

Official Protocol Title:	A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older
NCT number:	NCT05569954
Document Date:	15-May-2023

Title Page

THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME LLC, RAHWAY, NJ, USA (MSD).

Protocol Title: A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older

Protocol Number: 010-01

Compound Number: V116

Sponsor Name: Merck Sharp & Dohme LLC (hereafter called the Sponsor or MSD)

Legal Registered Address:

126 East Lincoln Avenue
P.O. Box 2000
Rahway, NJ 07065 USA

Regulatory Agency Identifying Number(s):

NCT	NCT05569954
EU CT	2022-503144-40
EudraCT	2022-001785-35
JRCT	Not Applicable
WHO	Not Applicable
UTN	Not Applicable
IND	Not Applicable

Approval Date: 15 May 2023

Sponsor Signatory

Typed Name: _____ Date _____
Title: _____

Protocol-specific Sponsor contact information can be found in the Investigator Study File Binder (or equivalent).

Investigator Signatory

I agree to conduct this clinical study in accordance with the design outlined in this protocol and to abide by all provisions of this protocol.

Typed Name: _____ Date _____
Title: _____

DOCUMENT HISTORY

Document	Date of Issue	Overall Rationale
Amendment 01	15-MAY-2023	The primary reason for this amendment is to update the superiority success criterion for serotype 15C.
Original Protocol	11-JUL-2022	Not applicable

PROTOCOL AMENDMENT SUMMARY OF CHANGES

Amendment: 01

Overall Rationale for the Amendment:

The primary reason for this amendment is to update the superiority success criterion for serotype 15C.

SUMMARY OF CHANGES TABLE

Section Number and Name	Description of Change	Brief Rationale
Primary Reason for Amendment		
1.1 Synopsis 3 Hypotheses, Objectives, and Endpoints 4.2.1.1 Immunogenicity Endpoints 9.1 Statistical Analysis Plan Summary 9.6.1 Statistical Methods for Immunogenicity Analyses	For hypothesis 2 (H2), the statistical superiority criterion for serotype 15C was revised for consistency with the criteria for the other unique serotypes in V116.	This change was made to address agency request. Although serotype 15B (contained in PPSV23, the comparator) may induce cross-reactive immune responses to serotype 15C (contained in V116) due to the similar polysaccharide capsule structure, the criterion to assess superiority of serotype 15C induced immune response in V116 recipients versus PPSV23 recipients has been aligned with those of the other unique serotypes for consistency.
Other Changes in Amendment		
Throughout document	The structure of the protocol has been updated.	To comply with current industry regulations and guidelines. This restructuring does not affect the clinical or regulatory integrity of the protocol. All other relevant changes and their primary reasons are included for completeness.
Title Page	Added EU CT number.	To comply with current guidelines in the EU.
1.1 Synopsis	Removed “in V116” from cross-reactive serotypes 6C and 15B.	For clarity.
1.1 Synopsis	Removed the statement “end of this study corresponds to the primary and secondary objectives and endpoints”.	Refer to Section 1.1 rationale.
1.2 Schema	Updated Figure 1 and footnote d to include PBMC blood draw at Visit 3.	To add missing PBMC assessment at Visit 3.
2.2.1 Pharmaceutical and Therapeutic Background	Clarified that serotype 20A is referred to as serotype 20 throughout the protocol.	Refer to Section 1.1 rationale.
3 Hypotheses, Objectives, and Endpoints	Removed “in V116” from cross-reactive serotypes 6C and 15B.	Refer to Section 1.1 rationale.
4.4 Beginning and End-of-Study Definition	Removed text defining the end of this study as corresponding to the primary and secondary objectives and endpoints.	Refer to Section 1.1 rationale.

Section Number and Name	Description of Change	Brief Rationale
5.2 Exclusion Criteria	Added a reference to country-specific criteria in Appendix 7.	To reference the South Korea-specific exclusion criteria added to Appendix 7.
6.1 Study Intervention Administration	Terminology in the Dose Formulation column of Table 1 (Study Interventions) was revised. “Sterile Solution (Prefilled Syringe)” was revised to “Injection, Solution” and “Sterile Suspension (Prefilled Syringe)” was revised to “Injection, Suspension”.	To align with ISO standards.
7.3 Lost to Follow-up	Deleted note defining lost to follow-up.	To allow a participant to be considered lost to follow-up as appropriate for the study.
8.2 Immunogenicity Assessments	Removed text regarding optional consent for FBR.	To align with ICF.
8.9 Future Biomedical Research Sample Collection	Added that leftover serum from the trial can be used for FBR.	To allow for an additional 5 years of storage and testing of serum.
10.1.6 Compliance with Study Registration and Results Posting Requirements	Updated references to EU regulations.	To comply with EU CTR requirements.
10.7.1 Country-specific Requirements for South Korea	Added a South Korea-specific version of Exclusion Criterion 13. Individuals who participate in an interventional clinical study with an investigational compound or device within 6 months of participating in this clinical study will be excluded.	To align with current guidelines in South Korea.
Throughout document	Minor administrative, formatting, grammatical, and/or typographical changes were made throughout the protocol.	To ensure clarity and accurate interpretation of the intent of the protocol, including alignment of terms with MedDRA preferred terminology.

Table Of Contents

DOCUMENT HISTORY	3
PROTOCOL AMENDMENT SUMMARY OF CHANGES.....	4
1 PROTOCOL SUMMARY	13
1.1 Synopsis.....	13
1.2 Schema	19
1.3 Schedule of Activities.....	20
1.3.1 Schedule of Activities for All Participants (Day 1 through Month 6).....	20
1.3.2 Schedule of Additional Activities for Immunogenicity Follow-up Substudy (Months 6 through 24)	22
1.3.3 Schedule of Additional Activities for PBMC Substudy (Day 1 through Month 12).....	23
2 INTRODUCTION.....	24
2.1 Study Rationale.....	24
2.2 Background	24
2.2.1 Pharmaceutical and Therapeutic Background	24
2.2.2 Information on Other Study-related Therapy	26
2.2.2.1 PPSV23	26
2.2.2.2 Pneumococcal Vaccination Guidelines.....	26
2.3 Benefit/Risk Assessment.....	27
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS	28
4 STUDY DESIGN.....	31
4.1 Overall Design	31
4.2 Scientific Rationale for Study Design.....	32
4.2.1 Rationale for Endpoints	32
4.2.1.1 Immunogenicity Endpoints.....	32
4.2.1.2 Safety Endpoints	33
4.2.1.3 Future Biomedical Research.....	33
4.2.2 Rationale for the Use of Comparator	34
4.3 Justification for Dose	35
4.4 Beginning and End-of-Study Definition	35
4.4.1 Clinical Criteria for Early Study Termination	35
5 STUDY POPULATION	36
5.1 Inclusion Criteria	36
5.2 Exclusion Criteria	37
5.3 Lifestyle Considerations	39
5.4 Screen Failures	39
5.5 Participant Replacement Strategy.....	39

6	STUDY INTERVENTION	40
6.1	Study Intervention(s) Administered	40
6.1.1	Medical Devices.....	42
6.2	Preparation/Handling/Storage/Accountability	42
6.2.1	Dose Preparation.....	42
6.2.2	Handling, Storage, and Accountability.....	42
6.3	Measures to Minimize Bias: Randomization and Blinding	43
6.3.1	Intervention Assignment.....	43
6.3.2	Stratification.....	43
6.3.3	Blinding.....	43
6.4	Study Intervention Compliance	44
6.5	Concomitant Therapy	44
6.5.1	Rescue Medications and Supportive Care	44
6.6	Dose Modification	44
6.7	Intervention After the End of the Study	44
6.8	Clinical Supplies Disclosure	45
6.9	Standard Policies	45
7	DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT WITHDRAWAL	46
7.1	Discontinuation of Study Intervention	46
7.2	Participant Withdrawal From the Study	46
7.3	Lost to Follow-up	46
8	STUDY ASSESSMENTS AND PROCEDURES	47
8.1	Administrative and General Procedures	48
8.1.1	Informed Consent.....	48
8.1.1.1	General Informed Consent.....	48
8.1.1.2	Consent and Collection of Specimens for Future Biomedical Research.....	48
8.1.1.3	Consent for PBMC Substudy.....	49
8.1.2	Inclusion/Exclusion Criteria	49
8.1.3	Participant Identification Card.....	49
8.1.4	Medical History	49
8.1.5	Prior and Concomitant Medications Review	49
8.1.5.1	Prior Medications.....	49
8.1.5.2	Concomitant Medications	50
8.1.6	Assignment of Screening Number	50
8.1.7	Assignment of Treatment/Randomization Number	50
8.1.8	Study Intervention Administration	50
8.1.8.1	Timing of Dose Administration.....	51

8.1.9	Electronic Vaccination Report Card	51
8.1.10	Telephone Contact Questionnaire.....	51
8.1.11	Discontinuation and Withdrawal	52
8.1.11.1	Withdrawal From Future Biomedical Research	52
8.1.12	Participant Blinding/Unblinding.....	52
8.1.13	Calibration of Equipment.....	53
8.2	Immunogenicity Assessments	53
8.2.1	Multiplex Opsonophagocytic Assay	53
8.2.2	Pneumococcal Electrochemiluminescence Assay	54
8.2.3	Exploratory Memory B-Cell Responses	54
8.3	Safety Assessments.....	55
8.3.1	Physical Examinations	55
8.3.2	Pregnancy Testing.....	55
8.3.3	Body Temperature Measurement.....	55
8.3.4	Postvaccination Observation Period	55
8.3.5	Clinical Safety Laboratory Assessments	56
8.4	Adverse Events, Serious Adverse Events, and Other Reportable Safety Events.....	56
8.4.1	Time Period and Frequency for Collecting AE, SAE, and Other Reportable Safety Event Information	57
8.4.2	Method of Detecting AEs, SAEs, and Other Reportable Safety Events.....	59
8.4.3	Follow-up of AE, SAE, and Other Reportable Safety Event Information...59	
8.4.4	Regulatory Reporting Requirements for SAE	59
8.4.5	Pregnancy and Exposure During Breastfeeding	60
8.4.6	Disease-related Events and/or Disease-related Outcomes Not Qualifying as AEs or SAEs.....	60
8.4.7	Events of Clinical Interest.....	60
8.4.8	Medical Device and Drug–Device Combination Products – PQCs/Malfunctions.....	60
8.4.9	Adverse Events on the VRC	61
8.4.9.1	Solicited Adverse Event.....	61
8.4.9.2	Unsolicited Adverse Events.....	61
8.5	Treatment of Overdose.....	61
8.6	Pharmacokinetics.....	61
8.7	Pharmacodynamics.....	62
8.8	Biomarkers	62
8.9	Future Biomedical Research Sample Collection.....	62
8.10	Health Economics Medical Resource Utilization and Health Economics.....	62
8.11	Visit Requirements.....	62

8.11.1	Screening.....	62
8.11.2	Treatment Period/Vaccination Visit	62
8.11.3	Immunogenicity Follow-up Substudy.....	62
8.11.4	PBMC Substudy.....	62
9	KEY STATISTICAL CONSIDERATIONS	63
9.1	Statistical Analysis Plan Summary.....	63
9.2	Responsibility for Analyses/In-house Blinding	65
9.3	Hypotheses/Estimation	65
9.4	Analysis Endpoints.....	65
9.4.1	Immunogenicity Endpoints.....	65
9.4.2	Safety Endpoints	66
9.5	Analysis Populations.....	67
9.5.1	Immunogenicity Analysis Populations	67
9.5.2	Safety Analysis Populations	67
9.6	Statistical Methods.....	68
9.6.1	Statistical Methods for Immunogenicity Analyses	68
9.6.2	Statistical Methods for Safety Analyses	71
9.6.2.1	Overall Safety Assessment	72
9.6.3	Demographic and Baseline Characteristics	73
9.7	Interim Analyses	73
9.8	Multiplicity	74
9.9	Sample Size and Power Calculations	74
9.9.1	Sample Size and Power for Immunogenicity Analyses.....	74
9.9.2	Sample Size and Power for Safety Analyses	76
9.10	Subgroup Analyses.....	77
9.11	Compliance (Medication Adherence).....	77
9.12	Extent of Exposure.....	77
10	SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS	78
10.1	Appendix 1: Regulatory, Ethical, and Study Oversight Considerations	78
10.1.1	Code of Conduct for Clinical Trials.....	78
10.1.2	Financial Disclosure.....	80
10.1.3	Data Protection.....	81
10.1.3.1	Confidentiality of Data	81
10.1.3.2	Confidentiality of Participant Records.....	81
10.1.3.3	Confidentiality of IRB/IEC Information.....	81
10.1.4	Committees Structure.....	82
10.1.4.1	Executive Oversight Committee.....	82

10.1.4.2	External Data Monitoring Committee	82
10.1.4.3	Scientific Advisory Committee (SAC).....	82
10.1.5	Publication Policy	82
10.1.6	Compliance with Study Registration and Results Posting Requirements ...	83
10.1.7	Compliance with Law, Audit, and Debarment	83
10.1.8	Data Quality Assurance	84
10.1.9	Source Documents	84
10.1.10	Study and Site Closure.....	85
10.2	Appendix 2: Clinical Laboratory Tests.....	86
10.3	Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting.....	88
10.3.1	Definitions of Medication Error, Misuse, and Abuse	88
10.3.2	Definition of AE	88
10.3.3	Definition of SAE	89
10.3.4	Additional Events Reported.....	90
10.3.5	Recording AE and SAE	91
10.3.6	Reporting of AEs, SAEs, and Other Reportable Safety Events to the Sponsor	95
10.4	Appendix 4: Medical Device and Drug–Device Combination Products: Product Quality Complaints/Malfunctions: Definitions, Recording, and Follow-up	97
10.4.1	Definitions.....	97
10.4.2	Recording, Assessing Causality, and Follow-up of PQC/Malfunctions ...	98
10.5	Appendix 5: Contraceptive Guidance.....	99
10.5.1	Definitions.....	99
10.5.2	Contraceptive Requirements.....	100
10.6	Appendix 6: Collection and Management of Specimens for Future Biomedical Research.....	101
10.7	Appendix 7: Country-specific Requirements	106
10.7.1	Country-specific Requirements for South Korea.....	106
10.8	Appendix 8: Abbreviations	107
11	REFERENCES.....	109

LIST OF TABLES

Table 1	Study Interventions	41
Table 2	Reporting Periods and Time Frames for Adverse Events and Other Reportable Safety Events	58
Table 3	Solicited Adverse Events	61
Table 4	Analysis Strategy for Immunogenicity Variables	71
Table 5	Analysis Strategy for Safety Parameters	73
Table 6	Differences in Incidence of Adverse Event Rates Between the 2 Vaccination Groups That Can be Detected With an Approximately 80% Probability	76
Table 7	Protocol-required Safety Laboratory Assessments	86
Table 8	Blood Volumes for Participants Included in the Base Study	86
Table 9	Blood Volumes for Participants Included in the Immunogenicity Follow-up Substudy (Includes Blood Volumes Required for the Base Study)	86
Table 10	Blood Volumes for Participants Included in the PBMC Substudy (Includes Blood Volumes Required for the Base Study)	87
Table 11	Blood Volumes for Participants Included in the Immunogenicity Follow-up Substudy and PBMC Substudy (Includes Blood Volumes Required for the Base Study)	87

LIST OF FIGURES

Figure 1 Schema.....19

1 PROTOCOL SUMMARY

1.1 Synopsis

Protocol Title: A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older

Short Title: Safety and Immunogenicity of V116 in Adults 50 Years of Age or Older

Acronym: STRIDE-10

Hypotheses, Objectives, and Endpoints:

Hypotheses are aligned with objectives in the Objectives and Endpoints table.

Objectives and endpoints will be evaluated in pneumococcal vaccine-naïve adults ≥ 50 years of age who are administered a single dose of V116 or PPSV23. For the objectives in this study, the serotypes are categorized as follows:

- 12 common serotypes in V116 and PPSV23 (3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 17F, and 20)
- 9 unique serotypes in V116 (6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B)
- 2 cross-reactive serotypes (6C, 15B)

Primary Objective	Primary Endpoint
<ul style="list-style-type: none">• Objective: To evaluate the safety and tolerability of V116 as assessed by the proportion of participants with adverse events (AEs)	<ul style="list-style-type: none">• Solicited injection-site AEs from Day 1 through Day 5 postvaccination• Solicited systemic AEs from Day 1 through Day 5 postvaccination• Vaccine-related serious adverse events (SAEs) from Day 1 through 6 months postvaccination

<ul style="list-style-type: none">• Objective: To compare the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) at 30 days postvaccination with V116 versus PPSV23 <p>Hypothesis (H1): V116 is noninferior to PPSV23 as assessed by serotype-specific OPA GMTs at 30 days postvaccination for the 12 common serotypes in V116 and PPSV23.</p> <p>(The statistical criterion for noninferiority requires the lower bound of the 2-sided 95% confidence interval [CI] of the OPA GMT ratio [V116/PPSV23] to be >0.5.)</p> <p>Hypothesis (H2): V116 is superior to PPSV23 as assessed by serotype-specific OPA GMTs at 30 days postvaccination for the 9 unique serotypes in V116.</p> <ul style="list-style-type: none">• (The statistical criterion for superiority requires the lower bound of the 2-sided 95% CI of the OPA GMT ratio [V116/PPSV23] to be >2.0.)	<ul style="list-style-type: none">• Serotype-specific OPA responses
---	---

<ul style="list-style-type: none"> • Objective: To compare the proportions of participants with a ≥ 4-fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination with V116 versus PPSV23 for the unique serotypes in V116. <p>Hypothesis (H3): V116 is superior to PPSV23 as assessed by the proportions of participants with a ≥ 4-fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination for the 9 unique serotypes in V116.</p> <p>(The statistical criterion for superiority requires the lower bound of the 2-sided 95% CI of the differences [V116 – PPSV23] between the proportions of participants with a ≥ 4-fold rise from baseline to 30 days postvaccination to be >0.1.)</p>	<ul style="list-style-type: none"> • Serotype-specific OPA responses
<p>Secondary Objectives</p>	<p>Secondary Endpoints</p>
<ul style="list-style-type: none"> • Objective: To evaluate serotype-specific cross-reactive OPA responses from baseline to 30 days postvaccination with V116 for serotypes within a serogroup. <p>Hypothesis (H4): V116 induces an acceptable antibody response as assessed by the proportions of participants with a ≥ 4-fold rise in serotype-specific cross-reactive OPA responses from baseline to 30 days postvaccination for serotypes within a serogroup in V116.</p> <p>(The statistical criterion for an acceptable antibody response requires the lower bound of the 95% CI of proportions of participants with a ≥ 4-fold rise from baseline to 30 days postvaccination for V116 to be >0.5.)</p>	<ul style="list-style-type: none"> • Serotype-specific OPA responses

<ul style="list-style-type: none"> • Objective: To evaluate the serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) at 30 days postvaccination with V116 compared with PPSV23. 	<ul style="list-style-type: none"> • Serotype-specific IgG responses
<ul style="list-style-type: none"> • Objective: To evaluate the serotype-specific geometric mean fold rise (GMFR) and proportions of participants with a ≥ 4-fold rise in serotype-specific OPA and IgG responses from baseline to 30 days postvaccination with V116 and separately for PPSV23. 	<ul style="list-style-type: none"> • Serotype-specific OPA and IgG responses

Overall Design:

Study Phase	Phase 3
Primary Purpose	Prevention
Indication	Pneumococcal infection
Population	Adults ≥ 50 years of age
Study Type	Interventional
Intervention Model	Parallel This is a multi site study.
Type of Control	Active Control Without Placebo
Study Blinding	Double-blind with in-house blinding
Blinding Roles	Participants or Subjects, Investigator, Sponsor
Estimated Duration of Study	The Sponsor estimates that the study will require approximately 31 months from the time the first participant (or their legally acceptable representative) provides documented informed consent until the last participant's last study-related contact. For purposes of analysis and reporting, the overall study ends when the Sponsor receives the last laboratory result or at the time of final contact with the last participant, whichever comes last.

Number of Participants:

Approximately 1400 participants will be randomized, with approximately 700 participants in the V116 intervention group and 700 participants in the PPSV23 intervention group.

Intervention Groups and Duration:

Arm Name	Intervention Name	Unit Dose Strength(s)	Dosage Level(s)	Route of Administration	Regimen/ Treatment Period/ Vaccination Regimen	Use
V116	Pneumococcal 21-valent conjugate vaccine	4 µg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B)	0.5 mL	IM	Single Dose at Visit 1 (Day 1)	Test Product
PPSV23	Pneumococcal Vaccine, Polyvalent (23-valent)	25 µg of each PnPs antigen (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F)	0.5mL	IM	Single Dose at Visit 1 (Day 1)	Comparator

Other current or former name(s) or alias(es) for study intervention(s) are as follows: V116: polyvalent pneumococcal conjugate vaccine (pPCV).

Total Number of Intervention Groups/Arms	2
Duration of Participation	Each participant will participate in the study for approximately 6 months from the time the participant provides documented informed consent through the Month 6 contact. Approximately 50% of participants will participate for an additional 18 months beyond the Month 6 contact (24 months total) as part of an immunogenicity follow-up substudy. Approximately 80 participants enrolled at selected study sites will participate for an additional 6 months beyond the Month 6 contact (12 months total) as part of a PBMC substudy.

Study Governance Committees:

Executive Oversight Committee	Yes
Data Monitoring Committee	Yes
Clinical Adjudication Committee	No

Study governance considerations are outlined in Appendix 1.


Study Accepts Healthy Participants: Yes

A list of abbreviations is in Appendix 8.

1.2 Schema

The study design is depicted in Figure 1.

Figure 1 Schema



eVRC = electronic Vaccination Report Card; INCL/EXCL = inclusion/exclusion; PBMC=peripheral blood mononuclear cell; PE = physical examination; PPSV23=pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX™23); SAE = serious adverse event; TC=telephone contact.

^a Randomization will be stratified by age (50 to 64 years vs. 65 to 74 years vs. ≥75 years).

^b Visit 4 is a site visit for participants at study sites included in the PBMC substudy; for all other participants, Visit 4 is a TC.

^c Visit 5 is a site visit for participants included in the immunogenicity follow-up substudy and/or the PBMC substudy; for all other participants, Visit 5 is a TC.

^d Blood draws for PBMC evaluation at Visits 1, 3, 4, 5, and 6 are only for the participants at study sites included in the PBMC substudy.

^e Blood draw for immunogenicity assays at Visit 4 is only for participants at study sites included in the PBMC substudy.

^f Blood draw for immunogenicity assays at Visit 5 is only for participants included in the immunogenicity follow-up substudy and/or the PBMC substudy.

1.3 Schedule of Activities

1.3.1 Schedule of Activities for All Participants (Day 1 through Month 6)

Study Period:	Intervention and Follow-up					Notes
Visit Number:	1	2	3	4	5	
Visit Type:	Visit	TC	Visit	Visit/TC	Visit/TC	
Study Day:	Day 1	Day 7	Day 30	Month 3	Month 6	
Visit Window:	-	Day 7 to Day 10	Day 30 to Day 44	Day 76 to Day 104	Day 166 to Day 194	
Administrative Procedures						
Screening Procedures						
Informed Consent	X					Must be obtained before any study procedures are conducted.
Informed Consent for Optional FBR	X					Must be obtained before any sample collection.
Assignment of Screening Number	X					
Inclusion/Exclusion Criteria	X					
Medical History	X					
Postrandomization Procedures						
Assignment of Randomization Number	X					
Participant Identification Card	X					
Prior/Concomitant Medication and Nonstudy Vaccination Review	X	X	X	X	X	For participants not included in a substudy, medications used to treat an SAE will be reported after Day 30. For participants included in a substudy, medications used to treat an SAE, prohibited medications, and/or nonstudy vaccinations will be reported after Day 30.
V116/PPSV23 Administration (blinded)	X					
Provide Electronic Device or Configure Participant's Own Electronic Device for eVRC Data Collection	X					
Review eVRC Data With Participant		X	X			
Collect Electronic Device From Participants Who Received an Electronic Device			X			
Complete Telephone Contact Questionnaire				X	X	

Study Period:	Intervention and Follow-up					Notes
Visit Number:	1	2	3	4	5	For participants included in the immunogenicity follow-up substudy and/or PBMC substudy, additional procedures required to be performed are outlined in Section 1.3.2 (immunogenicity follow-up substudy) and Section 1.3.3 (PBMC substudy).
Visit Type:	Visit	TC	Visit	Visit/TC	Visit/TC	Visit 4 is a site visit only for participants included in PBMC substudy. Visit 5 is a site visit only for participants included in the immunogenicity follow-up substudy and/or PBMC substudy. Visits 4 and 5 are TCs for all other participants.
Study Day:	Day 1	Day 7	Day 30	Month 3	Month 6	
Visit Window:	-	Day 7 to Day 10	Day 30 to Day 44	Day 76 to Day 104	Day 166 to Day 194	
Safety Procedures						
Complete Physical Examination	X					Performed by investigator or medically qualified designee at screening and before vaccination.
Pregnancy Test (if applicable)	X					Females of reproductive potential must have a negative urine or serum test (consistent with local requirements and sensitive to ≤ 25 IU hCG) result before vaccination.
Body Temperature Measurement	X					Measured before vaccination. Participants with febrile illness within 72 hours before vaccination must be rescheduled.
Postvaccination Observation Period	X					Observed by blinded study-site personnel for at least 30 minutes postvaccination.
AE Monitoring	X	X	X	X	X	Nonserious AEs collected through Day 30 postvaccination; all SAEs and deaths collected through Month 6.
Immunogenicity Procedures						
Serum for Immunogenicity Assays	X		X			Visit 1 sample should be collected before vaccination.
Future Biomedical Research						
Blood (DNA) for FBR	X					For participants who provided FBR consent. Should be collected before vaccination at Visit 1, or at a later date as long as FBR consent is obtained before collection.
AE=adverse event; DNA=deoxyribonucleic acid; eVRC=electronic vaccination report card; FBR=future biomedical research; hCG=human chorionic gonadotropin; IU=international units; PBMC=peripheral blood mononuclear cell; PPSV23=pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX™23); SAE=serious adverse event; TC=telephone contact.						

1.3.2 Schedule of Additional Activities for Immunogenicity Follow-up Substudy (Months 6 through 24)

Study Period:	Long-term Immunogenicity Evaluation				Notes
Visit Number:	5	6	7	8	All assessments in Section 1.3.1 are also required.
Visit Type:	Visit	Visit	Visit	Visit	
Study Day:	Month 6	Month 12	Month 18	Month 24	
Visit Window:	Day 166 to Day 194	Day 346 to Day 374	Day 526 to Day 554	Day 706 to Day 734	
Administrative Procedures					
Concomitant Medication and Nonstudy Vaccination Review	X	X	X	X	Medications used to treat an SAE, prohibited medications, and nonstudy vaccinations should be reported.
Safety Procedures					
AE Monitoring	X	X	X	X	All vaccine-related SAEs and deaths (any cause) will be collected. Any SAEs or nonserious AEs related to a protocol-specified blood draw that the investigator becomes aware of should be reported to the Sponsor.
Immunogenicity Procedures					
Serum for Immunogenicity Assays	X	X	X	X	If a participant is included in both the immunogenicity follow-up and PBMC substudies, only 1 set of immunogenicity samples should be collected per visit.
AE=adverse event; PBMC=peripheral blood mononuclear cell; SAE=serious adverse event; TC=telephone contact.					

1.3.3 Schedule of Additional Activities for PBMC Substudy (Day 1 through Month 12)

Study Period:	PBMC Evaluation						Notes
Visit Number:	1	2	3	4	5	6	All assessments in Section 1.3.1 are also required.
Visit Type:	Visit	TC	Visit	Visit	Visit	Visit	
Study Day:	Day 1	Day 7	Day 30	Month 3	Month 6	Month 12	
Visit Window:	-	Day 7 to Day 10	Day 30 to Day 44	Day 76 to Day 104	Day 166 to Day 194	Day 346 to Day 374	
Administrative Procedures							
Screening Procedures							
Informed Consent for PBMC Substudy	X						Must be obtained before any sample collection.
Postrandomization Procedures							
Concomitant Medication and Nonstudy Vaccination Review				X	X	X	Medications used to treat an SAE, prohibited medications, and nonstudy vaccinations should be reported.
Safety Procedures							
AE Monitoring	X			X	X	X	All SAEs and deaths will be collected through Month 6. All vaccine-related SAEs and deaths (any cause) will be collected through Month 12. Any SAEs or nonserious AEs related to a protocol-specified blood draw that the investigator becomes aware of should be reported to the Sponsor.
Immunogenicity Procedures							
Serum for Immunogenicity Assays				X	X	X	If a participant is included in both the PBMC and immunogenicity follow-up substudies, only 1 set of immunogenicity samples should be collected per visit.
Blood for PBMC Evaluation	X		X	X	X	X	Visit 1 PBMC sample should be collected before vaccination. All PBMC samples should be collected after immunogenicity samples.
AE=adverse event; PBMC=peripheral blood mononuclear cell; SAE=serious adverse event; TC=telephone contact.							

2 INTRODUCTION

The Sponsor is developing an investigational polyvalent pneumococcal 21-valent conjugate vaccine (V116) for the prevention of pneumococcal disease caused by the serotypes in the vaccine.

2.1 Study Rationale

Streptococcus pneumoniae is a major cause of vaccine-preventable disease worldwide. It is associated with considerable morbidity and mortality, with the highest burden in children <5 years and adults >70 years of age [Troeger, C., et al 2018]. PCV vaccination has reduced the incidence of disease caused by vaccine serotypes in the age groups being vaccinated (primarily children <5 years of age in most countries) and has had an indirect effect in other age groups.

However, an unmet medical need exists as increases in IPD due to serotypes not included in licensed PCVs have been observed in several countries, especially in adults.

V116 is an investigational PCV designed to address this unmet need and includes *S pneumoniae* serotypes not included in licensed PCVs, which account for the majority of IPD observed in adults.

This Phase 3 clinical study is being conducted to provide safety and immunogenicity data of V116 in adults ≥ 50 years of age who are at elevated risk for pneumococcal disease and associated morbidity and mortality due to aging-related physiological changes in the respiratory system, age related immunosenescence, and an increased incidence of other medical conditions associated with increased risk for pneumococcal disease [Drijkoningen, J. J 2014] [Janssens, J. P. 2004].

2.2 Background

To date, a Phase 1/2 study (V116-001) and a Phase 1 study in Japan (V116-002) have been conducted with V116. Results from the Phase 1 part of V116-001 were used to select the optimal vaccine formulation for subsequent development. Results from both studies showed that V116 is immunogenic and has acceptable safety and tolerability in healthy adults. Refer to the IB for detailed background information on V116.

2.2.1 Pharmaceutical and Therapeutic Background

Pneumococcal disease (ie, disease caused by *S pneumoniae*) is one of the single largest vaccine-preventable causes of death in children and older adults (≥ 65 years of age) worldwide. PCV use in children has decreased the incidence of disease caused by vaccine serotypes and has led to indirect protection in unvaccinated individuals from other age groups. This has resulted in a decrease in hospital admissions for pneumococcal disease in adults ≥ 65 years of age, including estimated decreases of 29% and 34% in admissions due to IPD and noninvasive pneumococcal pneumonia, respectively [Simonsen, L., et al 2014]. In some countries, including the US, the decrease in pneumococcal disease in children vaccinated with PCV has led to the recommendation to vaccinate adults with PCVs.

However, current surveillance does not definitively indicate that the use of PCVs in adults results in a similar reduction in pneumococcal disease [Matanock, A. 2018].

There is a residual burden of disease in adults that reflects the difference in serotype distribution in adults compared with infants and children. An increasing incidence of disease due to serotypes not included in the licensed PCVs has been observed, particularly in adults [Miller, Elizabeth, et al 2011] [Moore, M. R., et al 2015] [Pilishvili, T. 2015] [van der Linden, M., et al 2015] [Golden, A. R., et al 2016]. Increases in IPD cases due to nonvaccine serotypes (3, 7F, and 19A after implementation of PCV7; 22F and 33F after widespread usage of PCV13) have been observed in both pediatric and older adult (≥ 65 years of age) populations in the US [Hicks, L. A., et al 2007] [Pilishvili, Tamara, et al 2010] [Waight, P. A., et al 2015] [Moore, M. R., et al 2015] [Demczuk, W. H. B., et al 2013]. Similarly, due to the limited serotype coverage of the currently licensed vaccines in the EU, serotype replacement due to nonvaccine serotypes is being observed in older adults and may decrease the potential additional benefit of vaccination with currently available PCVs [European Center for Disease Prevention and Control 2018a].

Serotypes were selected for inclusion in V116 based on available global epidemiology data with a primary focus on data from older adults (≥ 65 years of age) in the US and EU, regions with an established pediatric vaccination program. V116 includes serotypes that are the largest contributors to adult residual disease, including select serotypes from PPSV23, PCV13, PCV15, and PCV20, as well as unique serotypes not included in any licensed pneumococcal vaccine. The V116 serotypes are responsible for $>80\%$ of adult disease IPD in the US, Germany, France, Canada, and Japan, approximately 90% of disease in the UK, and approximately 70% of disease in Australia, based on data from 2018 [Public Health Agency of Canada 2018b] [Demczuk, W. H. B., et al 2018] [Public Health England 2021] [Public Health England 2021a] [van der Linden, M., et al 2019] [Batah, J. 2018] [National Institute of Infectious Diseases 2018c] [Nakano, S., et al 2016]. In 2019, the most recent year for which serotype-specific data are available in both the EU and US, the serotypes in V116 accounted for 82% and 85% of IPD, respectively, in adults ≥ 65 years [European Centre for Disease Prevention and Control 2022] (Centers for Disease Control and Prevention, IPD serotype data 2019, as compiled from data provided through Active Bacterial Core surveillance [ABCs]).

V116 is designed to target serotypes that account for the majority of IPD in adults including serotypes not currently contained in any licensed pneumococcal vaccine, thereby addressing the unmet medical need of preventing residual pneumococcal disease in adults. It is being developed to support an indication for active immunization for the prevention of invasive disease and pneumonia caused by *S pneumoniae* serotypes 3, 6A, 6C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in adults 18 years of age and older. Note that serotype 15C represents deOAc15B as the molecular structures for deOAc15B and 15C are similar. Throughout this protocol serotype 20 refers to serotype 20A.

2.2.2 Information on Other Study-related Therapy

2.2.2.1 PPSV23

Refer to approved labeling for detailed background information on PPSV23.

PPSV23 is comprised of the polysaccharides from 23 of the serotypes causing disease in adults (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F). The formulation is not adjuvanted and no carrier protein is used.

PPSV23 was first approved in the US in 1983 and is currently registered and approved in >90 countries worldwide. PPSV23 is indicated for the prevention of pneumococcal disease in adults ≥ 50 years of age and in individuals ≥ 2 years of age at increased risk for pneumococcal disease.

2.2.2.2 Pneumococcal Vaccination Guidelines

Many countries have implemented age-based and/or risk-based recommendations for pneumococcal vaccination. Age-based recommendations typically start at 65 years of age due to the increased risk of pneumococcal disease associated with age.

Two expanded valent PCVs (PCV15 and PCV20), have been recently approved in the US and EU. In the US, the ACIP updated the vaccination guidelines to recommend that adults ≥ 65 years of age should receive either PCV15 followed by PPSV23, or PCV20 alone [Kobayashi, M., et al 2022]. It is expected that vaccination guidelines globally will be updated to include these newer PCVs. Currently, however, the vaccines that are broadly available in the majority of countries in the EU and other countries outside the US include a 23-valent polysaccharide vaccine (PPSV23) and a 13-valent protein-polysaccharide conjugate vaccines (PCV13). While there is variability in the vaccination guidelines, PPSV23 alone and PCV13 followed by PPSV23 are the 2 most common recommendations in European countries that have age-based guidelines for adults [European Centre for Disease Prevention and Control 2021b] [Bonnave, C., et al 2019]. However, despite national vaccination guidelines and recommendations from institutions such as the European Council and the World Coalition on Adult Vaccination, surveys have estimated that only 20% to 30% of adults ≥ 65 years of age in Europe are currently vaccinated [Independent Polling System Of Society 2017].

Risk-based recommendations generally include individuals with an increased risk of pneumococcal disease who are categorized as immunocompetent at-risk or as high-risk. Conditions associated with immunocompetent at-risk include, but are not limited to, chronic heart disease, chronic lung disease (including chronic obstructive pulmonary disease, emphysema, and asthma), diabetes mellitus, alcoholism, chronic liver disease (including cirrhosis), and cigarette smoking. Conditions associated with high-risk include, but are not limited to, congenital or acquired asplenia, sickle cell disease/other hemoglobinopathies, chronic renal failure, congenital or acquired immunodeficiencies, generalized malignancy, hematologic malignancy, HIV infection, nephrotic syndrome, solid organ transplant, and hematopoietic stem cell transplant [Kobayashi, M., et al 2022]. Recommendations for these groups with increased risk or high-risk vary across countries.

2.3 Benefit/Risk Assessment

It cannot be guaranteed that participants in clinical studies will directly benefit from treatment during participation, as clinical studies are designed to provide information about the safety and effectiveness of an investigational medicine.

Despite the public health impact of currently available pneumococcal vaccines, pneumococcal disease in adults remains a significant unmet medical need. *S pneumoniae* is a major cause of vaccine-preventable disease worldwide, resulting in considerable morbidity and mortality [Troeger, C., et al 2018].

Vaccination with PCVs has reduced the incidence of disease caused by vaccine serotypes in the population targeted by the vaccination (primarily children <5 years of age in most countries) and has had an indirect effect in other age groups. However, in several countries, infant vaccination with PCVs has also led to increases in IPD due to serotypes not included in the licensed PCVs, particularly in adults. This has resulted in an unmet medical need in this population.

V116 is designed to provide significantly broader pneumococcal disease coverage in adults as compared with currently licensed pneumococcal vaccines and is anticipated to have a generally comparable safety profile. No clinically important safety findings have been identified to date based on data from early phase clinical studies with V116.

The benefit-risk profile for V116 supports continued evaluation.

Approximately 50% of participants will receive PPSV23, a vaccine indicated for the prevention of pneumococcal disease in adults ≥ 50 years of age that is currently registered and approved in >90 countries worldwide. V116 is expected to provide comparable immune responses to PPSV23 for the common serotypes while providing additional coverage for the serotypes unique to V116. It is unknown if the investigational V116 will have the same clinical benefit as PPSV23.

Additional details regarding specific benefits and risks for participants participating in this clinical study may be found in the accompanying IB and informed consent documents.

3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS

Hypotheses are aligned with objectives in the Objectives and Endpoints table.

Objectives and endpoints will be evaluated in pneumococcal vaccine-naïve adults ≥ 50 years of age who are administered a single dose of V116 or PPSV23. For the objectives in this study, the serotypes are categorized as follows:

- 12 common serotypes in V116 and PPSV23 (3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 17F, and 20)
- 9 unique serotypes in V116 (6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B)
- 2 cross-reactive serotypes (6C, 15B)

Primary Objective	Primary Endpoint
<ul style="list-style-type: none"> • Objective: To evaluate the safety and tolerability of V116 as assessed by the proportion of participants with adverse events (AEs) 	<ul style="list-style-type: none"> • Solicited injection-site AEs from Day 1 through Day 5 postvaccination • Solicited systemic AEs from Day 1 through Day 5 postvaccination • Vaccine-related serious adverse events (SAEs) from Day 1 through 6 months postvaccination
<ul style="list-style-type: none"> • Objective: To compare the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) at 30 days postvaccination with V116 versus PPSV23 <p>Hypothesis (H1): V116 is noninferior to PPSV23 as assessed by serotype-specific OPA GMTs at 30 days postvaccination for the 12 common serotypes in V116 and PPSV23.</p> <p>(The statistical criterion for noninferiority requires the lower bound of the 2-sided 95% confidence interval [CI] of the OPA GMT ratio [V116/PPSV23] to be >0.5.)</p> <p>Hypothesis (H2): V116 is superior to PPSV23 as assessed by serotype-specific OPA GMTs at 30 days postvaccination for the 9 unique serotypes in V116.</p> <p>(The statistical criterion for superiority requires the lower bound of the 2-sided 95% CI of the OPA GMT ratio [V116/PPSV23] to be >2.0.)</p>	<ul style="list-style-type: none"> • Serotype-specific OPA responses

<ul style="list-style-type: none"> • Objective: To compare the proportions of participants with a ≥ 4-fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination with V116 versus PPSV23 for the unique serotypes in V116. Hypothesis (H3): V116 is superior to PPSV23 as assessed by the proportions of participants with a ≥ 4-fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination for the 9 unique serotypes in V116. (The statistical criterion for superiority requires the lower bound of the 2-sided 95% CI of the differences [V116 – PPSV23] between the proportions of participants with a ≥ 4-fold rise from baseline to 30 days postvaccination to be >0.1.) 	<ul style="list-style-type: none"> • Serotype-specific OPA responses
<p>Secondary Objectives</p>	<p>Secondary Endpoints</p>
<ul style="list-style-type: none"> • Objective: To evaluate serotype-specific cross-reactive OPA responses from baseline to 30 days postvaccination with V116 for serotypes within a serogroup. Hypothesis (H4): V116 induces an acceptable antibody response as assessed by the proportions of participants with a ≥ 4-fold rise in serotype-specific cross-reactive OPA responses from baseline to 30 days postvaccination for serotypes within a serogroup in V116. (The statistical criterion for an acceptable antibody response requires the lower bound of the 95% CI of proportions of participants with a ≥ 4-fold rise from baseline to 30 days postvaccination for V116 to be >0.5.) 	<ul style="list-style-type: none"> • Serotype-specific OPA responses
<ul style="list-style-type: none"> • Objective: To evaluate the serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) at 30 days postvaccination with V116 compared with PPSV23. 	<ul style="list-style-type: none"> • Serotype-specific IgG responses

<ul style="list-style-type: none">• Objective: To evaluate the serotype-specific geometric mean fold rise (GMFR) and proportions of participants with a ≥ 4-fold rise in serotype-specific OPA and IgG responses from baseline to 30 days postvaccination with V116 and separately for PPSV23.	<ul style="list-style-type: none">• Serotype-specific OPA and IgG responses
Tertiary/Exploratory Objectives	Tertiary/Exploratory Endpoints
<ul style="list-style-type: none">• Objective: To evaluate the cross-reactive immune responses to serotypes within a serogroup at 30 days postvaccination	<ul style="list-style-type: none">• Serotype-specific OPA and IgG responses
<ul style="list-style-type: none">• Objective (Immunogenicity Follow-up Substudy): To evaluate the durability of immune responses to V116 through 24 months postvaccination	<ul style="list-style-type: none">• Serotype-specific OPA and IgG responses
<ul style="list-style-type: none">• Objective (PBMC Substudy): To evaluate the ability of V116 to generate memory B-cell immune responses	<ul style="list-style-type: none">• Memory B-cell responses in peripheral blood mononuclear cells (PBMCs)

4 STUDY DESIGN

4.1 Overall Design

This is a randomized, active comparator-controlled, parallel-group, multisite, double-blind study of V116 in adults ≥ 50 years of age who have not previously received any pneumococcal vaccine (vaccine naïve).

Approximately 1400 participants will be randomized in a 1:1 ratio to receive a single dose of either V116 or PPSV23 on Day 1. Randomization will be stratified by participant age at enrollment (50 to 64 years, 65 to 74 years, and ≥ 75 years). At least 50% of participants will be ≥ 65 years of age.

An eVRC will be used by all participants to record solicited injection site AEs, solicited systemic AEs, and daily body temperature from Day 1 through Day 5 postvaccination. Unsolicited AEs will be collected through Day 30 postvaccination. All participants will be provided an electronic device or have their own electronic device configured, if compatible, to complete the eVRC.

Information for SAEs and deaths, regardless of whether the events are considered to be vaccine related by the investigator, will be collected through 6 months postvaccination.

Blood samples for immunogenicity assays will be drawn on Day 1 and at 30 days postvaccination (Visit 3) for all participants.

The first 50% of participants randomized will be followed for an additional 18 months after completing Visit 5 (for a total follow-up time of 24 months postvaccination) as part of an immunogenicity follow-up substudy. Blood samples will be drawn every 6 months starting at Month 6 (Visit 5) through Month 24 (Visit 8) for immunogenicity assays.

Approximately 80 participants randomized at selected study sites will participate in a PBMC substudy and will be followed for an additional 6 months after completing Visit 5 (for a total of 12 months postvaccination). Blood samples for PBMC evaluation will be drawn on Day 1, Day 30, and at 3, 6, and 12 months postvaccination.

Participants may be included in one or both of the substudies for immunogenicity follow-up and evaluation of PBMCs. During the substudies, vaccine-related SAEs, AEs (serious and nonserious) related to a blood draw, and deaths (any cause) will be collected. The results of the substudies will be summarized in a report separate from the CSR (Section 9.2).

An external DMC will conduct a periodic review of safety and tolerability data for the V116 Phase 3 program. A description of the structure and function of the DMC, along with the timing and content of the safety reviews, will be outlined in the DMC charter. Information regarding the composition of the DMC is provided in Appendix 1.

Specific procedures to be performed during the study, including prescribed times and associated visit windows, are outlined in Section 1.3.1 (all participants), Section 1.3.2 (participants included in the immunogenicity follow-up substudy), and Section 1.3.3

(participants at sites included in the PBMC substudy) of the SoA. Details of each procedure are provided in Section 8.

4.2 Scientific Rationale for Study Design

This study will evaluate the safety, tolerability, and immunogenicity of V116 in vaccine-naïve adults ≥ 50 years of age. This population is at increased risk for pneumococcal disease and its associated morbidity and mortality as the incidence of IPD is directly related to age, with over half of all cases occurring in adults ≥ 50 years of age [Drijkoningen, J. J 2014].

Adults with stable chronic medical conditions will be included in this study. These individuals are generally categorized as being immunocompetent at-risk, reflecting the understanding that while they are at an increased risk of pneumococcal disease, their immune responses are not impacted by the chronic medical condition [Curcio, D., et al 2015] [Weycker, D., et al 2010] [van Hoek, A. J., et al 2012].

The immunogenicity follow-up substudy will evaluate immune responses over time to assess durability of both IgG GMCs and OPA GMTs. There are limited data on the durability of immune responses of PCVs, and this assessment is intended to provide further insight into the potential protection that V116 may afford against pneumococcal disease.

The PBMC substudy will characterize serotype-specific memory B-cells in participants after vaccination. Conjugate vaccines, where an immunogenic protein is attached to an antigen, have been shown to induce immunologic memory, namely a memory B-cell response. PCVs are viewed to have an advantage compared with pneumococcal polysaccharide vaccines in the ability to induce a T-cell dependent response and subsequently induce memory B-cells. The PBMC substudy is being conducted to better understand the ability of V116 to result in the formation of memory B-cells.

4.2.1 Rationale for Endpoints

4.2.1.1 Immunogenicity Endpoints

The immunogenicity endpoints and associated statistical criteria are consistent with previous studies evaluating PCVs.

Sera from participants will be used to assess vaccine-induced, anti-PnPs, serotype specific OPA and IgG responses using the validated MOPA and Pn ECL assay, respectively. Immunogenicity endpoints will be evaluated for all serotypes included in V116 and for cross reactive serotypes within a serogroup.

Several studies have shown a positive correlation between serotype specific IgG antibody concentrations and OPA titers in children and adults [Centers for Disease Control and Prevention 2010] [Anttila, M., et al 1999] [Romero-Steiner, S., et al 1997]. OPA assesses levels of functional antibodies capable of opsonizing pneumococcal capsular polysaccharides for presentation to phagocytic cells for engulfment and subsequent killing; therefore, it is considered an important immunologic surrogate for protection against IPD in adults. It is

noted that IgG antibody concentration and OPA titer threshold values that correlate with protection in adults have not been defined; however, OPA responses are considered an accepted endpoint for the evaluation of novel pneumococcal vaccines in adults.

The primary immunogenicity endpoints in this study will be OPA responses. Serotypes common to both V116 and PPSV23 will be assessed for noninferiority, and serotypes unique to V116 will be assessed for superiority.

Secondary endpoints in this study include both OPA and IgG responses.

The OPA GMT, IgG GMC, GMFR, and proportion of participants with a 4-fold rise in OPA and IgG responses are acceptable assessments used to evaluate novel PCVs.

Exploratory endpoints in this study include both OPA and IgG responses, in addition to memory B-cell responses. Both IgG GMCs and OPA GMTs will be assessed to evaluate the durability of immune responses post vaccination with V116. The memory B-cell responses after vaccination with V116 will be characterized to understand the ability of V116 to induce a T-cell dependent B-cell response inferring induction of an immunological memory response.

Details on the immunogenicity endpoints evaluated in this study can be found in Section 9.4.1.

4.2.1.2 Safety Endpoints

Safety information will be collected from all participants on an eVRC. The eVRC used to record AEs during the postvaccination periods (Section 8.1.9) is structured as recommended in the final US FDA Patient-reported Outcome Guidance [U.S. Food and Drug Administration 2009].

The safety endpoints (ie, AEs and temperature) evaluated in this study are consistent with previous studies of V116 and published data from marketed PCVs. Detailed information for the safety endpoints evaluated in this study can be found in Section 9.4.2.

Definitions and reporting requirements for AEs are provided in Appendix 3.

4.2.1.3 Future Biomedical Research

The Sponsor will conduct FBR on specimens for which consent was provided during this study. This research may include genetic analyses (DNA), gene expression profiling (RNA), proteomics, metabolomics (serum, plasma), and/or the measurement of other analytes, depending on which specimens are consented for FBR.

Such research is for biomarker testing to address emergent questions not described elsewhere in the protocol and will only be conducted on specimens from appropriately consented participants. The objective of collecting/retaining specimens for FBR is to explore and identify biomarkers that inform the scientific understanding of diseases and/or their therapeutic treatments. The overarching goal is to use such information to develop safer,

more effective drugs/vaccines, and/or to ensure that participants receive the correct dose of the correct drug/vaccine at the correct time. The details of FBR research are presented in Appendix 6.

4.2.2 Rationale for the Use of Comparator

Placebo-controlled clinical studies for new PCVs are no longer practical, given the proven clinical efficacy and widespread use of licensed pneumococcal vaccines worldwide.

Of the currently licensed pneumococcal vaccines, PPSV23 affords the broadest serotype protection and has the most serotypes in common with V116. The serotypes in PPSV23 account for approximately 70% of IPD in the EU [Tin Tin Htar, M., et al 2015] [European Centre for Disease Prevention and Control 2020] [World Health Organization 2020a].

PPSV23-specific serotypes are often associated with severe disease [Grabenstein, J. D. 2014]. PPSV23 demonstrates approximately 73% efficacy against all-serotype IPD, up to approximately 77% effectiveness against vaccine-type IPD, and approximately 33% effectiveness against vaccine-type nonbacteremic pneumococcal pneumonia in healthy older adults [Suzuki, M., et al 2017] [Lawrence, H., et al 2020] [Kim, J. H., et al 2019].

Globally, PPSV23 is the pneumococcal vaccine most commonly recommended for the prevention of pneumococcal disease in adults. National Immunization Programs in several countries (ie, the UK, Germany, Japan) recommend PPSV23 for the prevention of pneumococcal disease in older adults. In several countries (ie, the US and Germany), PPSV23 is recommended in adults <65 years of age with certain underlying conditions that increase the risk of pneumococcal disease. Sequential vaccination with PCV13 followed by PPSV23 is commonly recommended for adults <65 years of age with immunocompromising conditions (ie, the US, Germany, Canada, Australia). Revaccination with PPSV23 is also recommended for immunocompetent older adults >65 years of age (ie, Japan) and in adults <65 years of age with certain underlying chronic or immunocompromising conditions (ie, Germany, Japan, Mexico).

PPSV23 offers clinical protection for an average of 10 years in most healthy adults and may decline with increasing age and time. Such observation is comparable to available data on the duration of protection afforded by PCV13 [Musher, D. M., et al 2010].

Revaccination with PPSV23 has been shown to elicit robust immune responses, and no reliable evidence of PPSV23 hyporesponsiveness exists after repeat vaccination ≥ 5 years after the previous dose [Musher, D. M., et al 2010] [Manoff, S. B., et al 2010] [Cripps, A. W., et al 2021].

PPSV23 has also been assessed to be cost-effective for pneumococcal vaccination, including revaccination, of older adults in many countries [Niederman, M. S., et al 2021] [Jiang, Y., et al 2018] [Thorrington, D., et al 2018] [Zhao, D., et al 2016].

With the above considerations, PPSV23 is included in this study as an appropriate comparator based on the demonstrated immunogenicity and effectiveness data available, coupled with the broad use in adults globally.

The use of PPSV23 in this study is consistent with the product labeling.

4.3 Justification for Dose

The V116 dose of 4 µg/each PnPs was selected based on review of safety and immunogenicity data from the Phase 1 and Phase 2 studies. In Phase 1, 2 doses of V116 were evaluated: a single dose containing 2 µg/each PnPs and a single dose of 4 µg/each PnPs. Based on the data from Phase 1, the V116 dose of 4 µg/each PnPs was selected for further evaluation in Phase 2. Results from Phase 2 showed that the V116 dose of 4 µg/each PnPs is well tolerated and generates serotype-specific immune responses. These data support the selection of the V116 dose of 4 µg/each PnPs for further development in Phase 3.

Refer to the IB for detailed background information on V116.

The dose of PPSV23 selected for use in this study is consistent with the approved dosing and product labeling of PNEUMOVAX™23.

4.4 Beginning and End-of-Study Definition

The overall study begins when the first participant (or their legally acceptable representative) provides documented informed consent. The overall study ends when the last participant completes the last study-related contact, withdraws consent, or is lost to follow-up (ie, the participant is unable to be contacted by the investigator).

For purposes of analysis and reporting, the overall study ends when the Sponsor receives the last laboratory test result or at the time of final contact with the last participant, whichever comes last.

If the study includes countries in the European Economic Area (EEA), the local start of the study in the EEA is defined as First Site Ready (FSR) in any Member State.

4.4.1 Clinical Criteria for Early Study Termination

The clinical study may be terminated early if the extent (incidence and/or severity) of emerging effects/clinical endpoints is such that the risk/benefit ratio to the study population as a whole is unacceptable. In addition, further recruitment in the study or at (a) particular study site(s) may be stopped due to insufficient compliance with the protocol, GCP, and/or other applicable regulatory requirements, procedure-related problems or the number of discontinuations for administrative reasons is too high.

5 STUDY POPULATION

As stated in the Code of Conduct for Clinical Trials (Appendix 1.1), this study includes participants of varying age (as applicable), race, ethnicity, and sex (as applicable). The collection and use of these demographic data will follow all local laws and participant confidentiality guidelines while supporting the study of the disease, its related factors, and the IMP under investigation.

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.

5.1 Inclusion Criteria

A participant is eligible for inclusion in the study if the participant meets all of the following criteria:

Type of Participant and Disease Characteristics

1. The participant may have underlying chronic conditions if they are assessed to be stable as per the investigator's judgment.

Demographics

2. Is an individual of any sex/gender, ≥ 50 years of age, at the time of informed consent.

Female Participants

3. A participant assigned female sex at birth is eligible to participate if not pregnant or breastfeeding, and at least one of the following conditions applies:
 - Not a POCBP
 - OR
 - A POCBP and:
 - Uses an acceptable contraceptive method, or is abstinent from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), as described in Appendix 5 during the intervention period and for at least 6 weeks after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention. Contraceptive use by POCBPs should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the local contraception requirements in the local label for any of the study interventions are more stringent than the requirements above, the local label requirements are to be followed.

- Has a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. Additional requirements for pregnancy testing during and after study intervention are in Section 8.3.2.
- Medical history, menstrual history, and recent sexual activity has been reviewed by the investigator to decrease the risk for inclusion of a POCBP with an early undetected pregnancy.

Informed Consent

4. The participant (or legally acceptable representative) has provided documented informed consent/assent for the study. The participant may also provide consent/assent for FBR. However, the participant may participate in the study without participating in FBR.

Additional Categories

5. The participant has the ability to complete eVRC data collection without assistance based on judgment of the investigator.

5.2 Exclusion Criteria

An individual must be excluded from the study if the individual meets any of the following criteria:

Medical Conditions

1. Has a history of IPD (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
2. Has a known hypersensitivity to any component of V116 or PPSV23, including diphtheria toxoid.
3. Has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented HIV infection, functional or anatomic asplenia, or history of autoimmune disease (including, but not limited to, the autoimmune conditions outlined in the Investigator Trial File Binder for this study).
4. Has a coagulation disorder contraindicating IM vaccination.
5. *Had a recent febrile illness (defined as oral or tympanic temperature $\geq 100.4^{\circ}\text{F}$ [$\geq 38.0^{\circ}\text{C}$] or axillary or temporal temperature $\geq 99.4^{\circ}\text{F}$ [$\geq 37.4^{\circ}\text{C}$]) or received antibiotic therapy for any acute illness occurring < 72 hours before receipt of study vaccine.

6. Has a known malignancy that is progressing or has required active treatment <3 years before enrollment. **Note:** Participants with basal cell and/or squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.

Prior/Concomitant Therapy

7. Received any prior pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside the protocol.
8. *Received systemic corticosteroids (prednisone equivalent of ≥ 20 mg/day) for ≥ 14 consecutive days and has not completed intervention ≥ 14 days before receipt of study vaccine. **Note:** Physiologic replacement doses (prednisone equivalent of approximately 5 mg/day), topical, ophthalmic, intraarticular or soft-tissue (eg, bursa, tendon steroid injections), and inhaled/nebulized steroids are permitted.
9. Is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
10. *Received any nonlive vaccine ≤ 14 days before receipt of study vaccine or is scheduled to receive any nonlive vaccine ≤ 30 days after receipt of study vaccine.
Exception: Inactivated influenza vaccine and SARS-CoV-2 mRNA or SARS-CoV-2 protein subunit vaccine may be administered but must be given ≥ 7 days before or ≥ 15 days after receipt of study vaccine.
11. *Received any live virus vaccine ≤ 30 days before receipt of study vaccine or is scheduled to receive any live virus vaccine ≤ 30 days after receipt of study vaccine.
12. Received a blood transfusion or blood products, including immunoglobulin ≤ 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product until the Day 30 postvaccination blood draw is complete. Autologous blood transfusions are not considered an exclusion criterion.

Prior/Concurrent Clinical Study Experience

13. Is currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.

Diagnostic Assessments

Not Applicable.

Other Exclusions

14. In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
15. Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
16. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.

For items with an asterisk (*), if the participant meets these exclusion criteria, Visit 1 may be rescheduled for a time when these criteria are not met.

Country-specific criteria are included in Appendix 7.

5.3 Lifestyle Considerations

No lifestyle restrictions are required.

5.4 Screen Failures

Screen failures are defined as participants who consent to participate in the clinical study, but are not subsequently randomized in the study. A minimal set of screen-failure information is required to ensure transparent reporting of screen-failure participants to meet the CONSORT publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen-failure details, eligibility criteria, and any AEs or SAEs meeting reporting requirements as outlined in the data entry guidelines.

5.5 Participant Replacement Strategy

A participant who withdraws from the study will not be replaced.

6 STUDY INTERVENTION

Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study participant according to the study protocol.

Clinical supplies (V116 and PPSV23) will be packaged to support enrollment. Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements.

6.1 Study Intervention(s) Administered

The study interventions to be used in this study are outlined in [Table 1](#).

Table 1 Study Interventions

Arm Name	Arm Type	Intervention Name	Intervention Type	Dose Formulation	Unit Dose Strength(s)	Dosage Level(s)	Route of Administration	Regimen/ Treatment Period/ Vaccination Regimen	Use	IMP or NIMP/ AxMP	Sourcing
V116	Experimental	Pneumococcal 21-valent conjugate vaccine	Biological/ Vaccine	Injection, Solution	4 µg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B)	0.5 mL	IM	Single Dose at Visit 1 (Day 1)	Test Product	IMP	Central
PPSV23	Active Comparator	Pneumococcal Vaccine, Polyvalent (23-valent)	Biological/ Vaccine	Injection, Solution	25 µg of each PnPs antigen (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F)	0.5mL	IM	Single Dose at Visit 1 (Day 1)	Comparator	IMP	Central or local

IM=intramuscular; IMP=investigational medicinal product; NIMP/AxMP=noninvestigational/auxiliary medicinal product; PnPs=pneumococcal polysaccharide; PPSV23=pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX™23); V116=pneumococcal 21-valent conjugate vaccine.

The classification of IMP and NIMP/AxMP in this table is based on guidance issued by the European Commission and applies to countries in the European Economic Area (EEA). Country differences with respect to the definition/classification of IMP and NIMP/AxMP may exist. In these circumstances, local legislation is followed.

All supplies indicated in [Table 1](#) will be provided per the “Sourcing” column depending on local country operational requirements. If local sourcing, every attempt should be made to source these supplies from a single lot/batch number where possible (eg, not applicable in the case where multiple lots or batches may be required due to the length of the study, etc).

Refer to Section 8.1.8 for details regarding administration of the study intervention.

6.1.1 Medical Devices

Drug-device combination product(s), which is legally marketed, provided for use in this study are: PNEUMOVAX™23 prefilled syringes. Refer to Section 8.4.8 and Appendix 4 for reporting events associated with these devices.

6.2 Preparation/Handling/Storage/Accountability

6.2.1 Dose Preparation

There are no specific calculations or evaluations required to be performed to administer the proper dose to each participant. The rationale for selection of doses to be used in this study is in Section 4.3.

Specific procedures that are required for dose preparation are outlined in the Investigator Trial File Binder.

As detailed in Section 6.3.3, study vaccines will be prepared by an unblinded member of the study-site staff.

6.2.2 Handling, Storage, and Accountability

The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study intervention received, and any discrepancies are reported and resolved before use of the study intervention.

Only participants enrolled in the study may receive study intervention, and only authorized site staff may supply or administer study intervention. All study interventions must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff.

The investigator, institution, or the head of the medical institution (where applicable) is responsible for study intervention accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records).

For all study sites, the local country Sponsor personnel or designee will provide appropriate documentation that must be completed for drug accountability and return, or local discard and destruction if appropriate. Where local discard and destruction is appropriate, the investigator is responsible for ensuring that a local discard/destruction procedure is documented.

The study site is responsible for recording the lot number, manufacturer, and expiry date for any locally purchased product (if applicable) as per local guidelines unless otherwise instructed by the Sponsor.

The investigator shall take responsibility for and shall take all steps to maintain appropriate records and ensure appropriate supply, storage, handling, distribution, and usage of study interventions in accordance with the protocol and any applicable laws and regulations.

6.3 Measures to Minimize Bias: Randomization and Blinding

6.3.1 Intervention Assignment

Intervention randomization will occur centrally using an IRT system. There are 2 study intervention arms. Participants will be assigned randomly in a 1:1 ratio to receive either V116 or PPSV23.

6.3.2 Stratification

Intervention randomization in the overall study will be stratified according to the following factors:

1. Participant age at time of randomization (50 to 64 vs. 65 to 74 vs. ≥ 75 years of age); at least 50% of participants will be ≥ 65 years of age.

6.3.3 Blinding

A double-blinding technique will be used. V116 and PPSV23 will be prepared and/or dispensed in a blinded fashion by an unblinded pharmacist or qualified study-site personnel.

The participant, the investigator, and Sponsor personnel or delegate(s) who are involved in the clinical evaluation of the participants are unaware of the intervention assignment.

Because V116 and PPSV23 have a different appearance, the unblinded pharmacist (or qualified study-site personnel) will be responsible for receiving, maintaining, preparing and/or dispensing, and administering these study vaccines (Section 8.1.8). To avoid bias, contact between the unblinded study site personnel and study participants is strictly prohibited for any study-related procedures/assessments other than administration of study vaccines. Blinded site personnel will be responsible for all other study procedures/assessments specified in Section 1.3.1. An unblinded Clinical Research Associate will monitor vaccine accountability at the study site. All Sponsor personnel or delegate(s) directly involved with the conduct of this study will remain blinded to the participant-level intervention assignment until all participants have completed the Month 6 visit. The participant and investigator will remain blinded to the participant-level intervention assignment throughout the duration of the study.

See Section 8.1.12 for a description of the method of unblinding a participant during the study should such action be warranted.

6.4 Study Intervention Compliance

Given that a single dose of V116 or PPSV23 will be administered in this study, intervention compliance will not be assessed.

6.5 Concomitant Therapy

Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed during the ongoing study (Section 5.2). The investigator should discuss any questions regarding this with the Sponsor Clinical Director. The final decision on any supportive therapy or vaccination rests with the investigator and/or the participant's primary physician.

It is important to record the use of any analgesic or antipyretic medication that occurs on the day of vaccination on the eVRC and appropriate eCRF.

Listed below are specific restrictions for concomitant therapy or vaccination:

- Administration of a nonstudy pneumococcal vaccine is prohibited during the study.
- Nonstudy vaccines may only be administered before or after the receipt of study vaccine according to the time frames specified in the Exclusion Criteria (Section 5.2).
- Receipt of systemic corticosteroids (prednisone equivalent ≥ 20 mg/day) for ≥ 14 consecutive days is prohibited from 14 days before vaccination through 30 days following vaccination. **Note:** physiologic replacement doses (prednisone equivalent of approximately 5 mg/day), topical, ophthalmic, intraarticular or soft-tissue (eg, bursa, tendon steroid injections), and inhaled/nebulized steroids are permitted.

Any deviation from the above requires consultation between the investigator and the Sponsor and written documentation of the collaborative decision on participant management.

Use of prior and concomitant medications/vaccinations should be recorded as described in Section 8.1.5.

6.5.1 Rescue Medications and Supportive Care

No rescue or supportive medications are specified for use in this study.

6.6 Dose Modification

No dose modification is allowed in this study.

6.7 Intervention After the End of the Study

There is no study-specified intervention after the end of the study.

6.8 Clinical Supplies Disclosure

This study is blinded but supplies are provided as open label; therefore, an unblinded pharmacist or qualified study-site personnel will be used to blind supplies. Study intervention identity (name, strength, or potency) is included in the label text; random code/disclosure envelopes or lists are not provided.

The emergency unblinding call center will use the intervention/randomization schedule for the study to unblind participants and to unmask study intervention identity. . The emergency unblinding call center should only be used in cases of emergency (see Section 8.1.12). If the emergency unblinding call center is not available for a given site in this study, the central electronic intervention randomization system (IRT) should be used to unblind participants and to unmask study intervention identity. The Sponsor will not provide random code/disclosure envelopes or lists with the clinical supplies.

See Section 8.1.12 for a description of the method of unblinding a participant during the study, should such action be warranted.

6.9 Standard Policies

Not applicable.

7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT WITHDRAWAL

7.1 Discontinuation of Study Intervention

In clinical studies with a single intervention, discontinuation of study intervention can only occur before the intervention and generally represents withdrawal from the study.

Participants who receive a single-dose intervention cannot discontinue study intervention.

7.2 Participant Withdrawal From the Study

A participant must be withdrawn from the study if the participant or participant's legally acceptable representative withdraws consent from the study.

If a participant withdraws from the study, they will no longer receive study intervention or be followed at scheduled protocol visits.

Specific details regarding procedures to be performed at the time of withdrawal from the study, as well as specific details regarding withdrawal from FBR, are outlined in Section 8.1.11. The procedures to be performed should a participant repeatedly fail to return for scheduled visits and/or if the study site is unable to contact the participant are outlined in Section 7.3.

7.3 Lost to Follow-up

If a participant fails to return to the clinic for a required study visit and/or if the site is unable to contact the participant, the following procedures are to be performed:

- The site must attempt to contact the participant and reschedule the missed visit. If the participant is contacted, the participant should be counseled on the importance of maintaining the protocol-specified visit schedule.
- The investigator or designee must make every effort to regain contact with the participant at each missed visit (eg, telephone calls and/or a certified letter to the participant's last known mailing address or locally equivalent methods). These contact attempts should be documented in the participant's medical record.

8 STUDY ASSESSMENTS AND PROCEDURES

- Study procedures and their timing are summarized in the SoA.
- Adherence to the study design requirements, including those specified in the SoA, is essential and required for study conduct.
- The investigator is responsible for ensuring that procedures are conducted by appropriately qualified (by education, training, and experience) staff. Delegation of study-site personnel responsibilities will be documented in the Investigator Trial File Binder (or equivalent).
- All study-related medical decisions must be made by an investigator who is a qualified physician.
- All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The investigator will maintain a screening log to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.
- Procedures conducted as part of the participant's routine clinical management (eg, blood count) and obtained before providing documented informed consent may be used for screening or baseline purposes provided the procedures meet the protocol-specified criteria and were performed within the time frame defined in the SoA.
- Additional evaluations/testing may be deemed necessary by the investigator and or the Sponsor for reasons related to participant safety. In some cases, such evaluation/testing may be potentially sensitive in nature (eg, HIV, hepatitis C), and thus local regulations may require that additional informed consent be obtained from the participant. In these cases, such evaluations/testing will be performed in accordance with those regulations.

The maximum amount of blood collected from each participant over the duration of the base study will not exceed 70 mL (Table 8).

For participants included in the immunogenicity follow-up substudy, an additional 120 mL of blood will be collected (maximum amount of blood collected from each participant will not exceed 190 mL [Table 9]).

For participants included in the PBMC substudy, an additional 340 mL of blood will be collected (maximum amount of blood collected from each participant will not exceed 410 mL [Table 10]).

For participants included in both the immunogenicity follow-up substudy and the PBMC substudy, the maximum amount of blood collected from each participant will not exceed 470 mL (Table 11).

Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the samples.

8.1 Administrative and General Procedures

8.1.1 Informed Consent

The investigator or medically qualified designee (consistent with local requirements) must obtain documented informed consent from each potential participant (or their legally acceptable representative) prior to participating in this clinical study or FBR. If there are changes to the participant's status during the study (eg, health or age of majority requirements), the investigator or medically qualified designee must ensure the appropriate documented informed consent is in place.

8.1.1.1 General Informed Consent

Informed consent given by the participant or their legally acceptable representative must be documented on a consent form. The form must include the study protocol number, study protocol title, dated signature, and agreement of the participant (or his/her legally acceptable representative) and of the person conducting the consent discussion.

A copy of the signed and dated informed consent form should be given to the participant (or their legally acceptable representative) before participation in the study.

The initial ICF, any subsequent revised ICF, and any written information provided to the participant must receive the IRB/IEC's approval/favorable opinion in advance of use. The participant or his/her legally acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the participant's willingness to continue participation in the study. The communication of this information will be provided and documented via a revised consent form or addendum to the original consent form that captures the participant's or the participant's legally acceptable representative's dated signature.

Specifics about the study and the study population are to be included in the study informed consent form.

Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and Sponsor requirements.

8.1.1.2 Consent and Collection of Specimens for Future Biomedical Research

The investigator or medically qualified designee will explain the FBR consent to the participant, or the participant's legally acceptable representative, answer all of his/her questions, and obtain documented informed consent before performing any procedure related to FBR. A copy of the informed consent will be given to the participant before performing any procedure related to FBR.

8.1.1.3 Consent for PBMC Substudy

The investigator or medically qualified designee will explain the consent for the PBMC substudy to the participant, or the participant's legally acceptable representative, answer all of their questions, and obtain documented informed consent before performing any procedure related to the PBMC substudy. A copy of the informed consent will be given to the participant.

8.1.2 Inclusion/Exclusion Criteria

All inclusion and exclusion criteria will be reviewed by the investigator, who is a qualified physician, to ensure that the participant qualifies for the study.

8.1.3 Participant Identification Card

All participants will be given a participant identification card identifying them as participants in a research study. The card will contain study-site contact information (including direct telephone numbers) to be used in the event of an emergency. The investigator or qualified designee will provide the participant with a participant identification card immediately after the participant provides documented informed consent. At the time of intervention randomization, site personnel will add the treatment/randomization number to the participant identification card.

The participant identification card also contains contact information for the emergency unblinding call center so that a health care provider can obtain information about study intervention in emergency situations where the investigator is not available.

8.1.4 Medical History

A medical history will be obtained by the investigator or qualified designee. The participant's relevant medical history for the 5 years before Visit 1 will be obtained to ensure that the participant satisfies the inclusion and exclusion criteria of the study. History of tobacco use will be collected for all participants.

8.1.5 Prior and Concomitant Medications Review

8.1.5.1 Prior Medications

The investigator or qualified designee will review and record prior vaccinations and medication taken by the participant within 30 days before study vaccination at Visit 1.

The following must be documented before vaccination at Visit 1 and recorded on the appropriate eCRF:

- Any analgesic or antipyretic medication taken on the day of vaccination before vaccination.

8.1.5.2 Concomitant Medications

The investigator or qualified designee will record vaccinations and medications, if any, taken by the participant during the study.

Any analgesic or antipyretic medication taken must be recorded on the eVRC and appropriate eCRF.

The participant will use their eVRC (Section 8.1.9) to record new and/or concomitant medications taken and nonstudy vaccines received from the day of vaccination through 30 days postvaccination.

After 30 days postvaccination, the investigator or qualified designee will record any medications used to treat an SAE. For participants included in a substudy, the investigator or qualified designee will also record any prohibited medications and/or nonstudy vaccinations.

8.1.6 Assignment of Screening Number

All consented participants will be given a unique screening number that will be used to identify the participant for all procedures that occur before randomization. Each participant will be assigned only 1 screening number. Screening numbers must not be reused for different participants.

8.1.7 Assignment of Treatment/Randomization Number

All eligible participants will be randomly allocated and will receive a treatment/randomization number. The treatment/randomization number identifies the participant for all procedures occurring after treatment randomization. Once a treatment/randomization number is assigned to a participant, it can never be reassigned to another participant.

A single participant cannot be assigned more than 1 treatment/randomization number.

8.1.8 Study Intervention Administration

Unblinded study personnel will prepare and administer all study vaccines (Section 6.3.3). The unblinded study personnel who administer study vaccines should not have contact with participants for any other study-related procedures/assessments.

Blinded site personnel will not be present in the examination room when study vaccines are administered.

Study vaccines should be prepared and administered by appropriately qualified members of the study personnel (eg, physician, nurse, physician's assistant, nurse practitioner, pharmacist, or medical assistant) as allowed by local/state, country, and institutional guidance. Procedures for handling, preparing, and administering the unblinded vaccines are provided in the Investigator Trial File Binder.

Study vaccine will be administered as a single IM injection, preferably in the deltoid region of the participant's arm, according to the schedule specified in Section 1.3.1. Adequate treatment provision, including epinephrine and equipment for maintaining an airway, should be available for immediate use should an anaphylactic or anaphylactoid reaction occur [Centers for Disease Control and Prevention 2015].

8.1.8.1 Timing of Dose Administration

Study vaccines will be administered as indicated in Section 1.3.1. Vaccinations may be administered at any time of day and without regard to timing of meals.

All participants will be observed for at least 30 minutes after vaccination for any immediate reactions (Section 8.3.4). This observation must be performed by blinded site personnel (Section 6.3.3).

Participants must not have a fever reported within 72 hours before vaccination (Section 1.3.1 and Section 8.3.3).

Administration of pregnancy tests (if applicable) must be performed before vaccine administration.

The collection of blood samples should be performed before vaccine administration.

8.1.9 Electronic Vaccination Report Card

The eVRC is structured as recommended in the final US FDA Patient-reported Outcome Guidance [U.S. Food and Drug Administration 2009].

The participant will use the eVRC to record body temperature (Section 8.3.3), solicited injection-site AEs, and solicited systemic AEs (Section 8.4.9.1). Unsolicited AEs (Section 8.4.9.2), concomitant medications (including use of any analgesic or antipyretic medication), and nonstudy vaccinations (Section 8.1.5.2) will also be reported. Participants will be provided an electronic device or have their own electronic device configured, if compatible, to complete the eVRC.

The investigator or delegate will review the data captured on the eVRC with the participant as indicated in Section 1.3.1. Any differences between data reported by the participant on the eVRC and data entered into the clinical database must be clearly explained in the participant's source documents.

8.1.10 Telephone Contact Questionnaire

Site personnel will contact the participant (or the participant's legally acceptable representative, as applicable) as indicated in Section 1.3.1 to collect additional information based on a Telephone Contact Questionnaire provided by the Sponsor. Data to be reported from this discussion will include SAEs and/or any updates to previously reported safety information.

8.1.11 Discontinuation and Withdrawal

Participants who receive a single-dose intervention cannot discontinue study intervention (see Section 7.1).

Participants who withdraw from the study should be encouraged to complete all applicable activities scheduled for the final study visit at the time of withdrawal. Any AEs that are present at the time of withdrawal should be followed in accordance with the safety requirements outlined in Section 8.4.

8.1.11.1 Withdrawal From Future Biomedical Research

Participants may withdraw their consent for FBR. Participants may withdraw consent at any time by contacting the study investigator. If medical records for the study are still available, the investigator will contact the Sponsor using the designated mailbox (clinical.specimen.management@MSD.com). Subsequently, the participant's consent for FBR will be withdrawn. A letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the responsibility of the investigator to inform the participant of completion of withdrawal. Any analyses in progress at the time of request for withdrawal or already performed before the request being received by the Sponsor will continue to be used as part of the overall research study data and results. No new analyses would be generated after the request is received.

If the medical records for the study are no longer available (eg, if the investigator is no longer required by regulatory authorities to retain the study records) or the specimens have been completely anonymized, there will no longer be a link between the participant's personal information and their specimens. In this situation, the request for specimen withdrawal cannot be processed.

8.1.12 Participant Blinding/Unblinding

STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY EFFORT SHOULD BE MADE NOT TO UNBLIND.

For emergency situations where the investigator or medically qualified designee (consistent with local requirements) needs to identify the intervention used by a participant and/or the dosage administered, he/she will contact the emergency unblinding call center by telephone and make a request for emergency unblinding. As requested by the investigator or medically qualified designee, the emergency unblinding call center will provide the information to him/her promptly and report unblinding to the Sponsor. Before contacting the emergency unblinding call center to request unblinding of a participant's intervention assignment, the investigator who is a qualified physician should make reasonable attempts to enter the intensity grade of the AEs observed, the relation to study intervention, the reason thereof, etc, in the medical record. If it is not possible to record this assessment in the medical record before the unblinding, the unblinding should not be delayed.

If unblinding has occurred, the circumstances around the unblinding (eg, date, reason, and person performing the unblinding) must be documented promptly, and the Sponsor Clinical Director notified as soon as possible.

Once an emergency unblinding has taken place, the investigator, site personnel, and Sponsor personnel may be unblinded so that the appropriate follow-up medical care can be provided to the participant.

Participants whose treatment assignment has been unblinded by the investigator or medically qualified designee and/or nonstudy treating physician should continue to be monitored in the study.

Additionally, the investigator or medically qualified designee must go into the IRT system and perform the unblind in the IRT system to update drug disposition. If the emergency unblinding call center is not available for a given site in this study, the IRT system should be used for emergency unblinding if this is required for participant safety.

8.1.13 Calibration of Equipment

The investigator or qualified designee has the responsibility to ensure that any device or instrument used for a clinical evaluation/test during a clinical study that provides information about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. Documentation of equipment calibration must be retained as source documentation at the study site.

8.2 Immunogenicity Assessments

Sera from participants will be used to measure vaccine-induced OPA and IgG responses. These endpoints will be tested for all immunogenicity blood draws specified in Section 1.3.1, Section 1.3.2, and Section 1.3.3 (IgG responses only). For participants included in the PBMC substudy, blood from participants will be used to measure memory B-cell responses in PBMCs at the timepoints specified in Section 1.3.3.

Blood collection, storage, and shipment instructions for serum samples will be provided in the operations/laboratory manual.

After completion of immunogenicity testing to evaluate the study objectives and hypotheses, serum samples will be stored to conduct any additional study-related testing as requested by regulatory agencies or the Sponsor. Leftover sera from the study may be used for other purposes, such as the development and/or validation of pneumococcal assays after completion of all study-related immunogenicity testing.

8.2.1 Multiplex Opsonophagocytic Assay

The MOPA will be used for measuring OPA responses. Opsonization of pneumococci for phagocytosis is an important mechanism by which antibodies to polysaccharides protect against disease in vivo. The OPA assay is a useful tool for assessing the protective function

of serotype-specific antibodies and, therefore, the immunogenicity of pneumococcal vaccine formulations.

The MOPA is an antibody-mediated killing assay that measures the ability of human serum to kill *S pneumoniae* serotypes with the help of complement and phagocytic effector cells [Burton, Robert L. and Nahm, Moon H. 2006]. The ability of the assay to simultaneously test 4 serotypes at a time reduces the amount of serum needed for testing. The assay readout is the opsonization index, which is the reciprocal of the highest dilution that gives $\geq 50\%$ bacterial killing, as determined by comparison to assay background controls. The Sponsor has developed and optimized the MOPA in a high-throughput microcolony platform, which not only covers all 21 serotypes in V116, but also includes serotypes 6C and 15B so that antibodies induced by vaccine serotypes 6A and 15C but cross-reactive to serotypes 6C and 15B, respectively, can be measured. The assay has been validated for various performance parameters of the assay including precision, ruggedness, relative accuracy/dilutional linearity, and the limit of detection of the assay.

8.2.2 Pneumococcal Electrochemiluminescence Assay

Serotype-specific IgG will be measured using the Pn ECL assay to assess the concentration of binding antibodies to capsular polysaccharide of *S pneumoniae*.

The Sponsor has developed, optimized, and validated a multiplex, ECL-based detection method for the quantitation of IgG serotype-specific antibodies. This multiplexed ECL assay not only detects all 21 serotypes contained in V116 but also detects serotypes 6C and 15B so that antibodies induced by vaccine serotypes 6A and 15C but cross-reactive to serotypes 6C and 15B, respectively, can be measured. The ECL assay is based on the Meso-Scale Discovery technology, which employs disposable multispot microtiter plates. Briefly, PnPs are bound to the surface of 96-well 10 plex carbon microplates, and serum containing purported anti-PnPs antibodies is added. The anti-PnPs antibodies bind to the coated plates and form an antibody-antigen complex. The bound antibody-antigen complex can be detected using a ruthenium labeled anti-human IgG. Plates are read by measure of the chemiluminescent signal emitted from the ruthenium tag upon electrochemical stimulation initiated at the electrode surfaces of the microplates. To improve the specificity to the pneumococcal serotypes in the vaccine, CCI

CCI Assay validation studies showed excellent performance operating characteristics for precision (intraassay and interassay), dilutability, ruggedness (to different plate lots and analysts), relative accuracy, and specificity.

8.2.3 Exploratory Memory B-Cell Responses

PBMCs will be used to assess the cellular response to V116 over time. This assessment will include evaluation of memory B-cells with assays such as, but not limited to, ELISPOT. The memory B-cell ELISPOT is a well-established immunological protocol for enumeration of antigen-specific memory B-cells and has been frequently used in the pneumococcal research field to quantify serotype-specific memory B-cell responses postvaccination with pneumococcal antigens [Papadatou, I., et al 2019].

8.3 Safety Assessments

Details regarding specific safety procedures/assessments to be performed in this study are provided.

Planned time points for all safety assessments are provided in the SoA.

8.3.1 Physical Examinations

A complete physical examination will be conducted by an investigator or medically qualified designee (consistent with local requirements) per institutional standard before vaccination at Visit 1.

Findings related to the physical examinations should be documented in the source documents. Investigators should pay special attention to clinical signs related to previous serious illnesses.

8.3.2 Pregnancy Testing

A pregnancy test consistent with local requirements (sensitive to at least 25 IU hCG) must be performed before vaccination at Visit 1 in POCBP as described in Section 1.3.1.

Urine or serum tests can be used, and results must be negative before vaccination can occur. A detailed definition of POCBP is provided in Appendix 5.

- Pregnancy testing:
 - Pregnancy testing requirements for study inclusion are described in Section 5.1.
 - Additional serum or urine pregnancy tests may be performed, as determined necessary by the investigator or required by local regulation, to establish the absence of pregnancy at any time during the participant's participation in the study.

8.3.3 Body Temperature Measurement

Each participant's body temperature must be taken by study-site staff before vaccination as described in Section 1.3.1. The prevaccination temperature should be documented in the participant's source documents. Participants who have febrile illness (defined as oral or tympanic temperature $\geq 100.4^{\circ}\text{F}$ [$\geq 38.0^{\circ}\text{C}$]; axillary or temporal temperature $\geq 99.4^{\circ}\text{F}$ [$\geq 37.4^{\circ}\text{C}$]) <72 hours before vaccination must be rescheduled.

Participants will also record oral body temperature measurements using the eVRC (Section 8.1.9) from Day 1 to Day 5 postvaccination.

8.3.4 Postvaccination Observation Period

All participants will be observed for at least 30 minutes after vaccination for any immediate reactions. If any immediate AEs are observed during this period, the time at which the event occurred within this timeframe, as well as the event itself, any concomitant medications that were administered, and resolution of the event must be recorded on the appropriate eCRF.

8.3.5 Clinical Safety Laboratory Assessments

Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the SoA for the timing and frequency.

- The investigator or medically qualified designee (consistent with local requirements) must review the laboratory report, document this review, and record any clinically relevant changes occurring during the study in the AE section of the CRF. The laboratory reports must be filed with the source documents. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
- All protocol-required laboratory assessments, as defined in Appendix 2, must be conducted in accordance with the laboratory manual and the SoA.
- If laboratory values from nonprotocol-specified laboratory assessments performed at the institution's local laboratory require a change in study participant management or are considered clinically significant by the investigator (eg, SAE or AE or dose modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
- For any laboratory tests with values considered clinically significantly abnormal during participation in the study or within 30 to 44 days after the last dose of study intervention, every attempt should be made to perform repeat assessments until the values return to normal or baseline or if a new baseline is established as determined by the investigator.

8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety Events

The definitions of an AE or SAE, as well as the method of recording, evaluating, and assessing causality of AE and SAE and the procedures for completing and transmitting AE, SAE, and other reportable safety event reports can be found in Appendix 3.

Adverse events, SAEs, and other reportable safety events will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative).

The investigator and any designees are responsible for detecting, documenting, and reporting events that meet the definition of an AE or SAE as well as other reportable safety events. Investigators need to document if an SAE was associated with a medication error, misuse, or abuse.

Investigators remain responsible for following up AEs, SAEs, and other reportable safety events for outcome according to Section 8.4.3. The investigator, who is a qualified physician, will assess events that meet the definition of an AE or SAE as well as other reportable safety events with respect to seriousness, intensity/toxicity, and causality.

8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other Reportable Safety Event Information

All AEs, SAEs, and other reportable safety events that occur after the participant provides documented informed consent, but before randomization, must be reported by the investigator if they cause the participant to be excluded from the study, or are the result of a protocol-specified intervention, including, but not limited to washout or discontinuation of usual therapy, diet, placebo, or a procedure.

All nonserious AEs and other reportable safety events (excluding pregnancy and lactation exposure) must be reported by the investigator from the day of randomization through 30 days postvaccination.

All pregnancies and lactation exposure during breastfeeding must be reported by the investigator from the day of randomization through 6 weeks postvaccination.

All SAEs must be reported by the investigator through 6 months postvaccination, regardless of whether related to the study intervention.

Additionally, any SAE brought to the attention of an investigator at any time outside the period specified in the previous paragraph also must be reported immediately to the Sponsor if the event is either:

- A death that occurs before the participant completing the study, but outside the period specified in the previous paragraph.

OR

- An SAE that is considered by an investigator, who is a qualified physician, to be vaccine related.

Investigators are not obligated to actively seek AEs or SAEs or other reportable safety events in former study participants. However, if the investigator learns of any SAE, including a death, at any time after a participant has been discharged from the study, and the investigator considers the event to be reasonably related to the study intervention or study participation, the investigator must promptly notify the Sponsor.

All initial and follow-up AEs, SAEs, and other reportable safety events will be recorded and reported to the Sponsor or designee within the time frames as indicated in [Table 2](#).

Exception: A positive pregnancy test at the time of initial screening is not a reportable event unless the participant has received study intervention.

Table 2 Reporting Periods and Time Frames for Adverse Events and Other Reportable Safety Events

Type of Event	<u>Reporting Period:</u> Consent to Randomization/ Allocation	<u>Reporting Period:</u> Randomization/ Allocation Through Protocol- specified Follow-up Period	<u>Reporting Period:</u> After the Protocol- specified Follow-up Period	Time Frame to Report Event and Follow-up Information to Sponsor
NSAE	Report if: – due to protocol-specified intervention – causes exclusion – participant is receiving placebo run-in or other run-in treatment	Report all	Not required	Per data entry guidelines
SAE	Report if: – due to protocol-specified intervention – causes exclusion – participant is receiving placebo run-in or other run-in treatment	Report all	Report if: – drug/vaccine related. – any death until participant completion of study (Follow ongoing to outcome)	Within 24 hours of learning of event
Pregnancy/Lactation Exposure	Report if: – participant has been exposed to any protocol-specified intervention (eg, procedure, washout or run-in treatment including placebo run-in) Exception: A positive pregnancy test at the time of initial screening is not a reportable event.	Report all	Previously reported – Follow to completion/ termination; report outcome	Within 24 hours of learning of event
ECI (requiring regulatory reporting)	Report if: – due to intervention – causes exclusion	Report – potential DILI – requiring regulatory reporting	Not required	Within 24 hours of learning of event

Type of Event	<u>Reporting Period:</u> Consent to Randomization/ Allocation	<u>Reporting Period:</u> Randomization/ Allocation Through Protocol- specified Follow-up Period	<u>Reporting Period:</u> After the Protocol- specified Follow-up Period	Time Frame to Report Event and Follow-up Information to Sponsor
ECI (does not require regulatory reporting)	Report if: – due to intervention – causes exclusion	Report – non-DILI ECIs and those not requiring regulatory reporting	Not required	Within 5 calendar days of learning of event
Cancer	Report if: – due to intervention – causes exclusion	Report all	Not required	Within 5 calendar days of learning of event (unless serious)
Overdose	Report if: – receiving placebo run-in or other run- in medication	Report all	Not required	Within 5 calendar days of learning of event
DILI=drug-induced liver injury; ECI=event of clinical interest; NSAE=nonserious adverse event; SAE=serious adverse event.				

8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events

Care will be taken not to introduce bias when detecting AEs and/or SAEs and other reportable safety events. Open-ended and nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrence.

8.4.3 Follow-up of AE, SAE, and Other Reportable Safety Event Information

After the initial AE/SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts. All AEs, SAEs, and other reportable safety events, including pregnancy and exposure during breastfeeding, ECIs, cancer, and overdose will be followed until resolution, stabilization, until the event is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3). In addition, the investigator will make every attempt to follow all nonserious AEs that occur in randomized participants for outcome. Further information on follow-up procedures is given in Appendix 3.

8.4.4 Regulatory Reporting Requirements for SAE

Prompt notification (within 24 hours) by the investigator to the Sponsor of SAE is essential so that legal obligations and ethical responsibilities toward the safety of participants and the safety of a study intervention under clinical investigation are met.

The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The Sponsor will comply with country-specific regulatory requirements and global laws and regulations relating to safety reporting to regulatory authorities, IRB/IECs, and investigators.

Investigator safety reports must be prepared for SUSARs according to local regulatory requirements and Sponsor policy and forwarded to investigators as necessary.

An investigator who receives an investigator safety report describing an SAE or other specific safety information (eg, summary or listing of SAEs) from the Sponsor will file it along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.

8.4.5 Pregnancy and Exposure During Breastfeeding

Although pregnancy and infant exposure during breastfeeding are not considered AEs, any pregnancy or infant exposure during breastfeeding (spontaneously reported to the investigator or their designee) that occurs in a participant during the study are reportable to the Sponsor.

All reported pregnancies must be followed to the completion/termination of the pregnancy.

Any pregnancy complication will be reported as an AE or SAE.

The medical reason (example: maternal health or fetal disease) for an elective termination of a pregnancy will be reported as an AE or SAE. Prenatal testing showing fetus will be born with severe abnormalities/congenital anomalies that leads to an elective termination of a pregnancy will be reported as an SAE for the fetus.

Pregnancy outcomes of ectopic pregnancy, spontaneous abortion, missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as serious events (Important Medical Events). If the pregnancy continues to term, the outcome (health of infant) must also be reported.

8.4.6 Disease-related Events and/or Disease-related Outcomes Not Qualifying as AEs or SAEs

Not applicable for this study.

8.4.7 Events of Clinical Interest

There are no ECIs for this study.

8.4.8 Medical Device and Drug–Device Combination Products – PQCs/Malfunctions

The method of documenting and reporting of such events (complaints associated with medical devices including PQCs/malfunctions) will occur as below and in Appendix 4.

To fulfill regulatory reporting obligations worldwide, medical device information associated with AEs will be collected and reported to the Sponsor in the same time frame as AEs per Section 8.4.1 via CRF (paper or electronic) and as per data entry guidelines.

PQCs/malfunctions, including those that involve a participant or any user/associated person, must be reported to the Sponsor. Sponsor shall review reported events by the investigator to fulfill the legal responsibility of notifying appropriate regulatory authorities and other entities about certain safety information relating to medical devices and drug-device combination products being used in clinical studies.

The investigator is responsible for ensuring that follow-up includes any supplemental investigations as indicated to elucidate the nature and/or causality between the AE and the medical device or device constituent of combination product.

8.4.9 Adverse Events on the VRC

Participants will use an eVRC to report solicited and unsolicited AEs.

The definitions of solicited and unsolicited AEs can be found in Appendix 3.

8.4.9.1 Solicited Adverse Event

Solicited AEs for this study are summarized in [Table 3](#).

Table 3 Solicited Adverse Events

Type of Solicited Adverse Event	Predefined Solicited Adverse Events (Preferred Term)	Solicited Period
Injection site	<ul style="list-style-type: none">Injection-site pain or tenderness (injection-site pain)Injection-site redness (injection-site erythema)Injection-site swelling (injection-site swelling)	Day 1 through Day 5 postvaccination
Systemic	<ul style="list-style-type: none">Headache (headache)Muscle aches all over body (myalgia)Tiredness (fatigue)	Day 1 through Day 5 postvaccination

8.4.9.2 Unsolicited Adverse Events

Unsolicited AEs for this study are events that are 1) not predefined in [Table 3](#) or 2) predefined in [Table 3](#) but reported at any time outside the solicited period.

8.5 Treatment of Overdose

In this study, an overdose is any dose higher than 1 dose of study vaccine in any 24-hour period.

No specific information is available on the treatment of overdose.

8.6 Pharmacokinetics

PK parameters will not be evaluated in this study.

8.7 Pharmacodynamics

Pharmacodynamic parameters will not be evaluated in this study.

8.8 Biomarkers

Biomarkers are not evaluated in this study.

8.9 Future Biomedical Research Sample Collection

If the participant provides documented informed consent for FBR, the following specimens will be obtained as part of FBR:

- DNA for future research
- Leftover serum from the trial

8.10 Health Economics Medical Resource Utilization and Health Economics

Medical Resource Utilization and Health Economics are not evaluated in this study.

8.11 Visit Requirements

Visit requirements are outlined in Section 1.3.1, Section 1.3.2, and Section 1.3.3. Specific procedure-related details are provided in Section 8.

8.11.1 Screening

Screening procedures will be conducted at Visit 1 as outlined in Section 1.3.1. Potential participants will be evaluated to determine that they fulfill the entry requirements as set forth in Section 5.

If Visit 1 is rescheduled (see Section 5.2), a pregnancy test (if applicable); a body temperature measurement; and a review of inclusion/exclusion criteria, prior medications/vaccinations, and medical history must be repeated before vaccination.

8.11.2 Treatment Period/Vaccination Visit

Requirements during the treatment period are outlined in Section 1.3.1.

8.11.3 Immunogenicity Follow-up Substudy

For participants included in the immunogenicity follow-up substudy, visit requirements are outlined in Section 1.3.2.

8.11.4 PBMC Substudy

For participants included in the PBMC substudy, visit requirements are outlined in Section 1.3.3.

9 KEY STATISTICAL CONSIDERATIONS

This section outlines the statistical analysis strategy and procedures for the study. If, after the study has begun, but prior to any unblinding/final database lock, changes are made to primary and/or key secondary hypotheses, or the statistical methods related to those hypotheses, then the protocol will be amended (consistent with ICH Guideline E-9). Changes to exploratory or other nonconfirmatory analyses made after the protocol has been finalized, but prior to any unblinding/final database lock, will be documented in a sSAP and referenced in the CSR for the study. Post hoc exploratory analyses will be clearly identified in the CSR.

9.1 Statistical Analysis Plan Summary

Key elements of the SAP are summarized below; the comprehensive plan is provided in Sections 9.2 through 9.12.

Study Design Overview	A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older.
Treatment Assignment	Approximately 1400 participants will be randomly assigned in a 1:1 ratio to receive V116 or PPSV23. Randomization will be stratified based on the participant's age (50 to 64 years, 65 to 74 years, and ≥ 75 years) at the time of randomization.
Analysis Populations	Immunogenicity: PP population Safety: APaT population
Primary Endpoint(s)	Immunogenicity: <ul style="list-style-type: none"> Serotype-specific OPA GMTs at 30 days postvaccination for the 21 serotypes contained in V116 Proportion of participants who achieve a ≥ 4-fold rise from baseline to 30 days postvaccination for OPA responses for the serotypes unique to V116 Safety: <ul style="list-style-type: none"> Proportion of participants with solicited injection-site AEs (redness/erythema, swelling, and tenderness/pain) from Day 1 through Day 5 postvaccination Proportion of participants with solicited systemic AEs (muscle aches all over body/myalgia, headache, and tiredness/fatigue) from Day 1 through Day 5 postvaccination Proportion of participants with vaccine-related SAEs from Day 1 through 6 months postvaccination
Key Secondary Endpoints	<ul style="list-style-type: none"> Serotype-specific IgG GMCs at 30 days postvaccination for the 21 serotypes contained in V116

<p>Statistical Methods for Key Immunogenicity Analyses</p>	<p>Immunogenicity analyses will be conducted separately for each of the 21 pneumococcal serotypes in V116 for the primary immunogenicity objectives. For the primary immunogenicity hypotheses:</p> <p>H1: V116 will be considered noninferior to PPSV23 if the lower bound of the 2-sided 95% CI of the OPA GMT ratio (V116/PPSV23) for each of the 12 common serotypes is >0.50.</p> <p>H2: V116 will be considered superior to PPSV23 if the lower bound of the 2-sided 95% CI of the OPA GMT ratio (V116/PPSV23) for each of the 9 unique serotypes contained in V116 is >2.0.</p> <p>For H1 and H2, estimation of the serotype-specific OPA GMT ratios, 95% CIs, and p-values will be calculated using the cLDA method [Liang, K-Y and Zeger, S. L. 2000].</p> <p>H3: V116 will be considered superior to PPSV23 if the lower bound of the 2-sided 95% CI of the difference (V116 – PPSV23) between proportions of participants with a ≥4-fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination is >0.1 for each of the 9 unique serotypes in V116. The between-group differences (V116 – PPSV23), 95% CIs, and p-values will be calculated using the stratified M&N method [Miettinen, O. and Nurminen, M. 1985].</p>
<p>Statistical Methods for Key Safety Analyses</p>	<p>For the overall safety evaluation, safety parameters will be summarized via descriptive statistics. For select safety parameters, between-group 95% CIs will be provided for the percentage of participants using the M&N method [Miettinen, O. and Nurminen, M. 1985].</p>
<p>Interim Analyses</p>	<p>To support the periodic review of safety and tolerability data across the adult V116 Phase 3 program, an external unblinded statistician will provide unblinded interim safety summaries to an independent external DMC for their review. Unblinded immunogenicity data will be made available to the DMC upon request to enable a benefit-risk assessment.</p>
<p>Multiplicity</p>	<p>The study will be considered to have met its primary immunogenicity objectives if noninferiority is demonstrated with respect to OPA GMTs for the 12 common serotypes, and superiority is demonstrated with respect to both OPA GMTs and the proportions of participants with ≥4-fold rises in OPA responses for the 9 unique serotypes in V116. Since comparisons are made individually for each of the 21 serotypes, this approach controls the 1-sided type-I error rate at 0.025, and no multiplicity adjustment is required.</p>
<p>Sample Size and Power</p>	<p>This study will randomize approximately 700 participants into the V116 group and 700 participants into the PPSV23 group. The overall power for all the primary hypotheses is >90% at an overall 1-sided 2.5% alpha-level.</p>

9.2 Responsibility for Analyses/In-house Blinding

The statistical analysis of the data obtained from this study will be the responsibility of the Clinical Biostatistics department of the Sponsor.

The base period of this study (Day 1 to 6 months postvaccination) will be conducted as a double-blind study under in-house blinding procedures. The official, final database for the base period will not be unblinded until medical/scientific review has been performed, protocol deviations have been identified, and data have been declared final and complete. Analyses on objectives to evaluate safety and tolerability through 6 months postvaccination and immunogenicity through 30 days postvaccination will be conducted, and a CSR will be written. Immunogenicity data beyond 30 days postvaccination will not be included in the CSR. The extension period of this study (6 months to up to 24 months postvaccination) will be conducted as a single-blind study. Investigators and study participants will remain blinded to individual vaccination assignments throughout the duration of the study. Results of the extension period will be presented in separate statistical reports from the CSR for the base period.

The Clinical Biostatistics department will generate the randomized allocation schedule(s) for study intervention assignment. Randomization will be implemented in an IRT system.

Blinding issues related to the planned IAs are described in Section 9.7.

9.3 Hypotheses/Estimation

Objectives and hypotheses of the study are stated in Section 3.

9.4 Analysis Endpoints

Immunogenicity and safety endpoints that will be evaluated for within- and/or between-intervention group differences are listed below.

9.4.1 Immunogenicity Endpoints

Immune responses will be measured for each of the serotypes contained in V116: the 12 serotypes in common with PPSV23 (3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 17F, and 20), the 9 unique serotypes contained in V116 (6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B), and 2 cross-reactive serotypes (6C and 15B).

The primary immunogenicity endpoints include:

- Serotype-specific OPA GMTs at 30 days postvaccination for the 21 serotypes contained in V116.
- Proportions of participants who achieve a ≥ 4 -fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination for the serotypes unique to V116.

The secondary immunogenicity endpoints for cross-reactive immune responses to serotypes within a serogroup include:

- Proportions of participants with a ≥ 4 -fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination with V116.

The secondary immunogenicity endpoints for all serotypes contained in V116 include:

- Serotype-specific IgG GMCs at 30 days postvaccination.
- Serotype-specific GMFRs and proportions of participants with a ≥ 4 -fold rise from baseline to 30 days postvaccination for both OPA and IgG responses.

The exploratory immunogenicity endpoints include:

- Serotype-specific OPA and IgG responses at 30 days postvaccination for the cross-reactive immune responses to serotypes within a serogroup.
- (Immunogenicity follow-up substudy) Serotype-specific OPA and IgG response through 24 months postvaccination.
- (PBMC Substudy) Memory B-cell responses for select serotypes in PBMCs at baseline, Day 30, and at 3, 6, and 12 months postvaccination.

9.4.2 Safety Endpoints

The safety endpoints for overall safety assessment that address the primary objective include:

- Proportion of participants with solicited injection-site AEs (redness/erythema, swelling, and tenderness/pain) from Day 1 through Day 5 postvaccination.
- Proportion of participants with solicited systemic AEs (muscle aches all over body/myalgia, headache, and tiredness/fatigue) from Day 1 through Day 5 postvaccination.
- Proportion of participants with vaccine-related SAEs from Day 1 through 6 months postvaccination.

Additional safety endpoints for overall safety assessment include:

- Proportion of participants with the broad AE categories consisting of any AE, any unsolicited AE, and any vaccine-related AE from Day 1 through Day 30 postvaccination.
- Proportion of participants with the broad AE categories consisting of any SAE, any vaccine-related SAE, and death from Day 1 through 6 months postvaccination.
- Proportion of participants with maximum temperature measurements meeting the Brighton Collaboration cut points from Day 1 through Day 5 postvaccination.

As this is a single-dose study, the broad AE category of discontinuation of study intervention due to an AE is not applicable.

9.5 Analysis Populations

9.5.1 Immunogenicity Analysis Populations

The PP population will serve as the primary population for the analysis of immunogenicity data in this study. The PP population consists of all randomized participants without deviations from the protocol that may substantially affect the results of the immunogenicity endpoint(s). Potential deviations that may result in the exclusion of a participant from the PP population for all immunogenicity analyses include:

- Failure to receive any study vaccine at Visit 1 (Day 1)
- Failure to receive correct clinical material as per randomization schedule at Visit 1 (Day 1)
- Receipt of prohibited medication or prohibited vaccine prior to study vaccination

Additional potential deviations that may result in the exclusion of a participant's measurement from a specific time point assessment in the PP population for immunogenicity analyses include:

- Receipt of prohibited medication or prohibited vaccine prior to a blood sample collection
- Collection of blood sample outside the prespecified window

The final determination on protocol deviations, and thereby the composition of the PP population, will be made before the final unblinding of the database and will be documented in a separate memo.

A supportive analysis using the FAS population will also be performed for the primary immunogenicity endpoints. The FAS population consists of all randomized participants who received study vaccination and have at least 1 serology result. Participants will be included in the vaccination group to which they are randomized for the analysis of immunogenicity data using the FAS population.

9.5.2 Safety Analysis Populations

Safety analyses will be conducted in the APaT population, which consists of all randomized participants who receive study intervention. Participants will be included in the group corresponding to the study intervention they actually receive for the analysis of safety data using the APaT population. This will be the group to which they are randomized except for participants who receive incorrect study intervention; such participants will be included in the intervention group corresponding to the study intervention actually received.

At least 1 temperature measurement obtained subsequent to study intervention is required for inclusion in the analyses of temperature.

9.6 Statistical Methods

9.6.1 Statistical Methods for Immunogenicity Analyses

This section describes the statistical methods that address the primary and secondary immunogenicity objectives. Methods related to exploratory objectives will be described in the sSAP.

Immunogenicity analyses will be conducted for each serotype separately.

Primary Endpoints/Hypotheses (H1 and H2)

The first primary objective (to compare the serotype-specific OPA GMTs at 30 days postvaccination with V116 versus PPSV23) will be assessed via the 2 hypotheses.

For the 12 common serotypes, the primary noninferiority hypothesis (H1) regarding OPA GMT levels between recipients of V116 and PPSV23 is:

H₀: GMT₁/GMT₂ ≤ 0.50 versus

H₁: GMT₁/GMT₂ > 0.50

where GMT₁ is the serotype-specific OPA GMT for the V116 group and GMT₂ is the serotype-specific OPA GMT for the PPSV23 group. A ratio of 0.50 corresponds to an OPA GMT that is 2.0-fold lower in the V116 group compared with the PPSV23 group. Rejecting the null hypothesis (H₀) at the 1-sided α=0.025 level corresponds to the lower bound of the 2-sided 95% CI on the GMT ratio (V116/PPSV23) being >0.50 and would lead to the conclusion that the OPA response to V116 for the common serotype is noninferior to that of PPSV23.

For the 9 serotypes that are unique to V116, the primary superiority hypothesis (H2) regarding OPA GMT levels between recipients of V116 and PPSV23 is:

H₀: GMT₁/GMT₂ ≤ 2.0 versus

H₁: GMT₁/GMT₂ > 2.0

where GMT₁ is the serotype-specific OPA GMT for the V116 group, and GMT₂ is the serotype-specific OPA GMT for the PPSV23 group. A ratio of 2.0 corresponds to an OPA GMT that is 2.0-fold higher in the V116 group compared with the PPSV23 group. Rejecting the null hypothesis (H₀) at the 1-sided α=0.025 level corresponds to the lower bound of the 2-sided 95% CI on the GMT ratio (V116/PPSV23) being >2.0 and would lead to the conclusion that the OPA response to V116 for the unique serotype is superior to that of PPSV23.

To address the first primary immunogenicity objective, the serotype-specific OPA GMTs at 30 days postvaccination will be compared between vaccination groups. The GMT ratio estimation, 95% CI, and the hypothesis test (ie, 1-sided p-value) will be calculated using a

cLDA method proposed by Liang and Zeger [Liang, K-Y and Zeger, S. L. 2000] using data from both vaccination groups. In this model, the response vector consists of the log-transformed antibody titers at baseline and 30 days postvaccination. The repeated measures model will include terms for time, vaccination group, the interaction of time-by-vaccination group, age stratum (ie, 50 to 64 years, 65 to 74 years, and ≥ 75 years of age) at vaccination, and the interaction of time-by-age stratum. This model will allow for different baseline means for each age stratum, but restrict the baseline mean within each age stratum to be the same for all vaccination groups. The term for time will be treated as a categorical variable. An unstructured covariance matrix will be used to model the correlation among repeated measurements. The Kenward-Roger adjustment will be used with REML to make proper statistical inference. This model allows the inclusion of participants who are missing either the baseline or postbaseline measurements, thereby increasing efficiency.

Primary Endpoint/Hypothesis (H3)

The second primary objective (to compare the proportions of participants with a ≥ 4 -fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination with V116 versus PPSV23) will be assessed via the following superiority hypotheses for the 9 serotypes that are unique to V116:

$$H_0: p_1 - p_2 \leq 0.1 \text{ versus}$$

$$H_1: p_1 - p_2 > 0.1$$

where p_1 and p_2 are the proportions of participants with a ≥ 4 -fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination for the V116 group and PPSV23 group, respectively. A difference of 0.1 corresponds to the V116 group having a 10% higher proportion of participants with a ≥ 4 -fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination than the PPSV23 group. Rejecting the null hypotheses (H_0) at the 1-sided $\alpha=0.025$ level corresponds to the lower bound of the 2-sided 95% CI on the difference (V116 – PPSV23) being >0.1 and would lead to the conclusion that the proportion of participants with a ≥ 4 -fold rise in OPA responses in the V116 group for the unique serotype is superior to that in the PPSV23 group.

To address the second primary immunogenicity objective, the proportion of participants with a ≥ 4 -fold rise in serotype-specific OPA responses will be compared between vaccination groups. Comparisons will be made through the estimation of the difference in the proportion of participants with a ≥ 4 -fold rise in serotype-specific OPA responses for the unique serotypes in V116. The participants who are missing either baseline or 30 days postvaccination OPA responses will not be included in the fold-rise calculation. Estimation of the proportion difference and 95% CI and the hypothesis test (ie, 1-sided p-value) will be conducted using the stratified M&N method, an unconditional, asymptotic method [Miettinen, O. and Nurminen, M. 1985].

Secondary Endpoint/Hypothesis (H4)

The first secondary objective (to demonstrate V116 induces an acceptable antibody response as assessed by the proportions of participants with a ≥ 4 -fold rise in serotype-specific cross reactive OPA responses from baseline to 30 days postvaccination for serotypes within a serogroup) will be assessed via the following hypothesis:

$H_0: p_1 \leq 0.5$ versus

$H_1: p_1 > 0.5$

where p_1 is the proportion of participants with a ≥ 4 -fold rise in serotype-specific cross reactive OPA responses from baseline to 30 days postvaccination for the V116 group.

Point estimate and the corresponding 95% CI will be computed using the exact binomial method of Clopper and Pearson [Clopper, C. J. and Pearson, E. S. 1934].

Other Secondary Endpoints

A similar statistical model as used for the first primary objective will be used to address the secondary objective that compares the serotype-specific IgG GMCs at 30 days postvaccination with V116 compared with PPSV23.

Descriptive statistics with point estimates and within-group 95% CIs will be provided for all other immunogenicity endpoints. For the continuous endpoints, the point estimates will be calculated by exponentiating the estimates of the mean of the natural log values and the within-group CIs will be derived by exponentiating the bounds of the CIs of the mean of the natural log values based on the t-distribution. For the dichotomous endpoints, the within-group CIs will be calculated based on the exact method proposed by Clopper and Pearson [CLOPPER, C. J. and PEARSON, E. S. 1934a].

Reverse Cumulative Distribution Curves for both OPA titers and IgG concentrations at 30 days postvaccination will be graphically displayed by serotype.

A detailed analysis strategy for immunogenicity endpoints is listed in [Table 4](#).

Table 4 Analysis Strategy for Immunogenicity Variables

Endpoint/Variable (Description, Time Point)	Primary vs. Supportive Approach ^a	Statistical Method	Analysis Population	Missing Data Approach
Primary Endpoints				
OPA GMTs at 30 days postvaccination for the 21 serotypes in V116	P	cLDA ^b (estimate, 95% CI, p-values)	PP	Model-based
	S		FAS	
Proportions of participants with a ≥ 4 -fold rise from baseline to 30 days postvaccination for OPA responses for the unique serotypes in V116	P	Stratified M&N ^c (estimate, 95% CI, p-values)	PP	Missing data will not be imputed
	S		FAS	
Secondary Endpoints				
Proportions of participants with a ≥ 4 -fold rise from baseline to 30 days postvaccination for OPA responses for the cross-reactive serotypes	P	Clopper-Pearson (estimate, 95% CI, p-values)	PP	Missing data will not be imputed
IgG GMCs at 30 days postvaccination for the 21 serotypes in V116	P	cLDA ^b (estimate, 95% CI)	PP	Model-based
GMFRs and proportions of participants with a ≥ 4 -fold rise from baseline to 30 days postvaccination for both OPA and IgG responses for the 21 serotypes in V116	P	Descriptive Statistics (estimate, 95% CI)	PP	Missing data will not be imputed
CI=confidence interval; cLDA=constrained longitudinal data analysis; FAS=full analysis set; GMC=geometric mean concentration; GMFR=geometric mean fold rise; GMT=geometric mean titer; IgG=immunoglobulin G; M&N=Miettinen and Nurminen; OPA=opsonophagocytic activity; PP=per-protocol. ^a P=Primary approach; S=Supportive approach. ^b cLDA model with terms for vaccination group, time, the interaction of time-by-vaccination, age stratum (ie, 50 to 64 years, 65 to 74 years, and ≥ 75 years), and interaction of time-by-age stratum. ^c Stratified analysis using the M&N method [Miettinen, O. and Nurminen, M. 1985] with stratification by the participant's age at the time of randomization (50 to 64 years of age, 65 to 74 years of age, and ≥ 75 years of age). Baseline is the day of vaccination (Day 1); 30 days postvaccination is the day of the Visit 3 blood draw (Day 30).				

9.6.2 Statistical Methods for Safety Analyses

Safety and tolerability will be assessed by clinical review of all relevant parameters, including AEs and postvaccination temperature measurements.

9.6.2.1 Overall Safety Assessment

The overall safety evaluation will include a summary by intervention group (V116 group and PPSV23 group) of the number and percentage of participants with any AEs, any unsolicited AEs, any vaccine-related AEs, any SAEs, any vaccine-related SAEs, and any AEs resulting in death after vaccination. Point estimates and 95% CIs for the between-group differences (V116 compared with PPSV23) in the percentages of participants with the event will be provided for these events.

The number and percentage of participants with specific AEs will also be provided. Point estimates and 95% CIs for the differences between intervention groups in the percentages of participants with specific AEs will be provided for solicited AEs and AEs that occur in $\geq 1\%$ of participants in the V116 group or PPSV23 group.

The above threshold for the numbers of events were chosen because the 95% CI for the between-group difference in percent incidence will always include zero when fewer participants per vaccination group have events and thus would add little to the interpretation of potentially meaningful differences.

The number and percentage of participants with maximum temperature measurements meeting the Brighton Collaboration cut points [Marcy, S. M., et al 2004] will be provided along with point estimates and 95% CIs of between-group differences.

CI for between-group differences will be provided using the M&N method [Miettinen, O. and Nurminen, M. 1985]. CIs that are not adjusted for multiplicity should only be regarded as helpful descriptive measures for the review of the safety profile and not as a formal method for assessing statistical significance of between group differences. Rainfall plots with point estimates and 95% CIs will be displayed for AEs that occur in $\geq 5\%$ of participants in the V116 group or PPSV23 group.

The analysis strategy for safety endpoints is summarized in [Table 5](#).

Any vaccine-related SAEs, any SAEs or nonserious AEs related to a blood draw reported to the Sponsor, and any deaths up to 24 months will be included in statistical reports for the extension period.

Table 5 Analysis Strategy for Safety Parameters

Analysis Part	Safety Endpoint	Descriptive Statistics	95% Between-group CI	Graphical Display
Overall Safety Assessment	Solicited injection-site AE (Day 1 through Day 5 postvaccination) ^a	X	X	
	Solicited systemic AE (Day 1 through Day 5 postvaccination) ^a	X	X	
	Any AE ^b	X	X	
	Any unsolicited AE ^b	X	X	
	Any vaccine-related AE ^b	X	X	
	Any SAE ^b	X	X	
	Any vaccine-related SAE ^b	X	X	
	Death ^b	X	X	
	Specific AEs by SOC and PT ^c	X	X	X
	Maximum temperatures (Day 1 through Day 5 postvaccination) ^d	X	X	
AE=adverse event; CI=Confidence Interval; PT=Preferred term; SAE=serious adverse event; SOC=System Organ Class. ^a Solicited injection-site AEs include redness/erythema, swelling, and tenderness/pain; solicited systemic AEs include muscle aches all over body/myalgia, headache, and tiredness/fatigue. ^b These endpoints are broad AE categories. For example, descriptive statistics for the safety endpoint of “Any AE” will provide the number and percentage of participants with at least 1 AE. ^c Descriptive statistics and graphical displays will be provided for specific AEs with an incidence >0% and ≥5% of participants, respectively, in either intervention group. The 95% between-group CI will be provided for specific AEs with an incidence ≥1% of participants in either intervention group. ^d Maximum temperature measurements are categorized by Brighton Collaboration cut points.				

9.6.3 Demographic and Baseline Characteristics

The comparability of the vaccination groups for each relevant demographic and baseline characteristic will be assessed using summary tables. No statistical hypothesis tests will be performed on these characteristics. The number and percentage of participants randomized and discontinued from the study and discontinuation reasons will be displayed. Demographic variables (eg, age, race, ethnicity, sex, and gender), baseline characteristics, and prior and concomitant vaccinations and medications will be summarized by vaccination group either by descriptive statistics or categorical tables.

9.7 Interim Analyses

A periodic review of safety and tolerability data across the V116 Phase 3 adult program will be conducted by an independent, unblinded, external DMC. A description of the structure and function of the DMC, along with the timing and content of the safety review, will be outlined in the DMC charter. Information regarding the composition of the DMC is provided in Appendix 1. In addition, unblinded immunogenicity data will be made available to the DMC upon request to enable a benefit-risk assessment.

The DMC will serve as the primary reviewer of the results of the ongoing safety reviews and will make recommendations for continuation of the study (with or without protocol modifications) or discontinuation of the study to an executive oversight committee of the Sponsor (see Appendix 1 for details on the Committees Structure for this study). If the DMC recommends modifications to the design of the protocol or discontinuation of the study, the oversight committee (and potentially other limited Sponsor personnel) may be unblinded to results at the intervention level to act on these recommendations. The extent to which individuals are unblinded with respect to ongoing safety reviews will be documented by the external unblinded statistician. Additional logistical details will be provided in the DMC charter.

Study enrollment may be ongoing at the time of external DMC review. Blinding to intervention assignment will be maintained at all investigational sites. Participant-level unblinding will be restricted to an external unblinded statistician performing ongoing safety reviews. Intervention-level ongoing safety reviews will be provided by the external unblinded statistician to the DMC. Before final unblinding of the base period of the study, the external unblinded statistician will not be involved in any discussions regarding modifications to the protocol, statistical methods, identification of protocol deviations, or data validation efforts after the safety reviews.

9.8 Multiplicity

The study will have met its primary immunogenicity objectives if noninferiority is demonstrated with respect to the OPA GMTs for the 12 common serotypes (via H1), and superiority is demonstrated with respect to both OPA GMTs and the proportions of participants with ≥ 4 -fold rises in OPA responses for the 9 unique serotypes (via H2 and H3). All hypotheses will be tested individually for each serotype at a 1-sided 0.025 alpha-level. This approach controls the 1-sided type-I error rate at 0.025, and no multiplicity adjustment will be required.

The secondary hypothesis (H4) will be used to assess the cross-reactive antibody responses induced by V116 for serotypes within a serogroup in V116. Each cross-reactive serotype will be tested for the acceptability of cross-reactive antibody responses induced by V116 at a 1-sided 0.025 alpha-level. If 1 cross-reactive serotype succeeds but the other cross-reactive serotype fails on the prespecified statistical criteria, the study will be considered to have met the secondary acceptability objective for the successful cross-reactive serotype. The 1-sided type-I error rate within each cross-reactive serotype will be controlled at 0.025.

9.9 Sample Size and Power Calculations

9.9.1 Sample Size and Power for Immunogenicity Analyses

This study will randomize approximately 700 participants into the V116 group and 700 participants into the PPSV23 group.

Primary Immunogenicity Endpoints/Hypotheses (H1, H2, H3)

For the primary hypotheses, this study has >90% power for demonstrating noninferiority to PPSV23 for the 12 common serotypes (H1) and superiority for the 9 unique serotypes for V116 (H2 and H3) at an overall 1-sided 2.5% alpha-level.

The sample size and power calculations are based on the following assumptions:

- For the 12 common serotypes, the underlying serotype-specific OPA GMT ratios (V116/PPSV23) and the standard deviations of natural log-transformed OPA results are assumed to be the same as that observed in V116-001 Phase 2. The OPA GMT ratios range from 0.94 to 2.57. The standard deviations range from 1.06 to 1.73 for V116 and range from 1.13 to 2.08 for PPSV23.
- For the 9 unique serotypes, the underlying serotype-specific OPA GMT ratios (V116/PPSV23) and the standard deviations of natural log-transformed OPA results are assumed to be the same as that observed in V116-001 Phase 2. The OPA GMT ratios range from 3.00 to 34.90. The standard deviations range from 1.25 to 1.95 for V116 and range from 1.57 to 2.89 for PPSV23.
- The underlying proportions of participants with a ≥ 4 -fold rise in OPA responses from baseline to 30 days postvaccination for V116 and PPSV23 are the same as those observed in V116-001 Phase 2 for the 9 unique serotypes. The underlying differences (V116 – PPSV23) between proportions of participants with a ≥ 4 -fold rise in OPA responses range from 0.18 to 0.68 for the unique serotypes.
- 90% evaluability rate (approximately 630 evaluable participants per intervention group).

Based on the assumptions above, the power for the primary hypotheses is calculated using a simulation-based approach. This approach uses the cLDA model and the M&N method for comparing OPA GMTs and proportions of participants with a 4-fold rise in OPA responses between the 2 vaccination groups, respectively. The power is estimated as the number of successful iterations out of the total iterations in the simulation. The success within each iteration is defined as meeting all primary hypotheses for each serotype (ie, noninferiority for the 12 common serotypes [H1] and superiority for the 9 unique serotypes [H2 and H3]).

Secondary Immunogenicity Endpoint/Hypothesis (H4)

For the secondary hypothesis H4, this study has >95% power at a 1-sided 2.5% alpha-level to demonstrate V116 induces an acceptable antibody response as assessed by the proportion of participants with a ≥ 4 -fold rise in serotype-specific cross-reactive OPA responses from baseline to 30 days postvaccination for each of the 2 cross-reactive serotype (6C and 15B). The power calculation for this secondary hypothesis is based on the following assumptions:

- The underlying serotype-specific proportions of participants with a ≥ 4 -fold rise from baseline to 30 days postvaccination in the V116 group are 0.58 and 0.71 for serotypes 6C and 15B, respectively, the same as those observed in V116-001 Phase 2.
- 90% evaluability rate (approximately 630 evaluable participants in the V116 group).

9.9.2 Sample Size and Power for Safety Analyses

The probability of observing at least 1 SAE in this study depends on the number of participants vaccinated and the underlying incidence of participants with an SAE in the study population. Calculations below assume that 100% of the randomized participants will be evaluable for safety analyses.

There is an 80% chance of observing at least 1 SAE among 700 participants in V116 group if the underlying incidence of an SAE is 0.23% (1 of every 435 participants receiving the vaccine). There is a 50% chance of observing at least 1 SAE among 700 participants in the V116 group if the underlying incidence of an SAE is 0.10% (1 of every 1010 participants receiving the vaccine). If no SAEs are observed among 700 participants, this study will provide 97.5% confidence that the underlying percentage of participants with an SAE is <0.53% (1 in every 190 participants) in the V116 group.

The percentage point differences between the 2 vaccination groups that could be detected with 80% probability are summarized in Table 6 for a variety of hypothetical underlying incidences of an AE.

Table 6 Differences in Incidence of Adverse Event Rates Between the 2 Vaccination Groups That Can be Detected With an Approximately 80% Probability

Incidence of Adverse Event		Risk Difference
V116 (%) N=700	PPSV23 (%) N=700	Percentage Points
1.4	0.1	1.3
4.7	2.0	2.7
8.8	5.0	3.8
14.9	10.0	4.9
20.7	15.0	5.7
26.3	20.0	6.3
37.1	30.0	7.1

The incidences presented here are hypothetical and do not represent actual adverse experiences in either group. The incidences assume a 2-sided 5% alpha level with 700 participants in each group. No multiplicity adjustments were made.
 The calculations are based on an asymptotic method proposed by Farrington and Manning [Farrington, C. P. 1990].

9.10 Subgroup Analyses

Subgroup analyses will be performed separately for select safety endpoints as well as primary immunogenicity endpoints. The following subgroups are planned for evaluation:

- Age category (50 to 64, 65 to 74, ≥ 75 years of age)
- Sex
- Race
- Ethnicity
- Chronic medical condition

Further details of subgroup analyses will be documented in the sSAP.

9.11 Compliance (Medication Adherence)

Given that participants will receive a single dose of V116 or PPSV23, compliance will not be calculated. However, the number and proportion of randomized participants receiving V116 or PPSV23 will be summarized (Section 9.12).

9.12 Extent of Exposure

The extent of exposure will be summarized by the number and proportion of randomized participants administered V116 or PPSV23.

10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS

10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations

10.1.1 Code of Conduct for Clinical Trials

Merck Sharp & Dohme LLC, Rahway, NJ, USA (MSD)

Code of Conduct for Interventional Clinical Trials

I. Introduction

A. Purpose

MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conducted in compliance with local and/or national regulations (including all applicable data protection laws and regulations), and International Council for Harmonisation Good Clinical Practice (ICH-GCP), and also in accordance with the ethical principles that have their origin in the Declaration of Helsinki.

B. Scope

Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by MSD irrespective of the party (parties) employed for their execution (e.g., contract research organizations, collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or which are retrospective. Further, this Code does not apply to investigator-initiated trials, which are not under the full control of MSD.

II. Scientific Issues

A. Trial Conduct

1. Trial Design

Except for pilot or estimation trials, clinical trial protocols will be hypothesis-driven to assess safety, efficacy and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine patient preferences, etc.

The design (i.e., participant population, duration, statistical power) must be adequate to address the specific purpose of the trial and shall respect the data protection rights of all participants, trial site staff and, where applicable, third parties. All trial protocols are and will be assessed for the need and capability to enroll underrepresented groups. Participants must meet protocol entry criteria to be enrolled in the trial.

2. Site Selection

MSD's clinical trials are conducted globally in many different countries and in diverse populations, including people of varying age, race, ethnicity, gender, and accounting for other potential disease related factors. MSD selects investigative sites based on medical expertise, access to appropriate participants, adequacy of facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial initiation, sites are evaluated by MSD personnel (or individuals acting on behalf of MSD) to assess the ability to successfully conduct the trial.

Where appropriate, and in accordance with regulatory authority guidance, MSD will make concerted efforts to raise awareness of clinical trial opportunities in various communities. MSD will seek to engage underrepresented groups and those disproportionately impacted by the disease under study. MSD will support

clinical trial investigators to enroll underrepresented groups and expand access to those who will ultimately use the products under investigation.

3. Site Monitoring/Scientific Integrity

Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus source documentation according to standard operating procedures. Per MSD policies and procedures, if potential fraud, scientific/research misconduct, privacy incidents/breaches or Clinical Trial-related Significant Quality Issues are reported, such matters are investigated. When necessary, appropriate corrective and/or preventative actions are defined and regulatory authorities and/or ethics review committees are notified.

B. Publication and Authorship

Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of marketed products in which treatment is assigned, according to the pre-specified plans for data analysis. To the extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis-generating rather than hypothesis testing; in such cases, publication of results may not be appropriate since the trial may be underpowered and the analyses complicated by statistical issues such as multiplicity.

MSD's policy on authorship is consistent with the recommendations published by the International Committee of Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in publications.

III. Participant Protection

A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics Committee [IEC])

All protocols and protocol amendments will be submitted by MSD for regulatory authority acceptance/authorization prior to implementation of the trial or amendment, in compliance with local and/or national regulations.

The protocol, protocol amendment(s), informed consent form, investigator's brochure, and other relevant trial documents must be reviewed and approved by an IRB/IEC before being implemented at each site, in compliance with local and/or national regulations. Changes to the protocol that are required urgently to eliminate an immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval. MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance with local and/or national regulations.

B. Safety

The guiding principle in decision-making in clinical trials is that participant welfare is of primary importance. Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial designs will take into account the local standard of care.

All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is obtained. Participants may withdraw from an MSD trial at any time, without any influence on their access to, or receipt of, medical care that may otherwise be available to them.

C. Confidentiality

MSD is committed to safeguarding participant confidentiality, to the greatest extent possible, as well as all applicable data protection rights. Unless required by law, only the investigator, Sponsor (or individuals acting on behalf of MSD), ethics committee, and/or regulatory authorities will have access to confidential medical records that might identify the participant by name.

D. Genomic Research

Genomic research will only be conducted in accordance with a protocol and informed consent authorized by an ethics committee.

IV. Financial Considerations

A. Payments to Investigators

Clinical trials are time- and labor-intensive. It is MSD's policy to compensate investigators (or the sponsoring institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be made to compensate for the time spent in extra recruiting efforts.

MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent on chart review and medical evaluation to identify potentially eligible participants.

B. Clinical Research Funding

Informed consent forms will disclose that the trial is sponsored by MSD, and that the investigator or sponsoring institution is being paid or provided a grant for performing the trial. However, the local ethics committee may wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.

C. Funding for Travel and Other Requests

Funding of travel by investigators and support staff (e.g., to scientific meetings, investigator meetings, etc.) will be consistent with local guidelines and practices.

V. Investigator Commitment

Investigators will be expected to review MSD's Code of Conduct as an appendix to the trial protocol, and in signing the protocol, agree to support these ethical and scientific standards.

10.1.2 Financial Disclosure

Financial disclosure requirements are outlined in the US Food and Drug Administration Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54). It is the Sponsor's responsibility to determine, based on these regulations, whether a request for financial disclosure information is required. It is the investigator's/subinvestigator's responsibility to comply with any such request.

The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to allow for the submission of complete and accurate certification and disclosure statements. The investigator/subinvestigator(s) further agree to provide this information on a Certification/Disclosure Form, frequently known as a financial disclosure form, provided by the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this

information to the Sponsor in the United States for these purposes. This may involve the transmission of information to countries that do not have laws protecting personal data.

10.1.3 Data Protection

The Sponsor will conduct this study in compliance with all applicable data protection regulations.

Participants will be assigned a unique identifier by the Sponsor. Any participant records or datasets that are transferred to the Sponsor will contain the identifier only; participant names or any information that would make the participant identifiable will not be transferred.

The participant must be informed that his/her personal study-related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the participant.

The participant must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.

10.1.3.1 Confidentiality of Data

By signing this protocol, the investigator affirms to the Sponsor that information furnished to the investigator by the Sponsor will be maintained in confidence, and such information will be divulged to the IRB, IEC, or similar or expert committee, affiliated institution, and employees, only under an appropriate understanding of confidentiality with such board or committee, affiliated institution, and employees. Data generated by this study will be considered confidential by the investigator, except to the extent that it is included in a publication as provided in the Publications section of this protocol.

10.1.3.2 Confidentiality of Participant Records

By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to verify worksheet/CRF data. By signing the consent form, the participant agrees to this process. If study documents will be photocopied during the process of verifying worksheet/CRF information, the participant will be identified by unique code only; full names/initials will be masked before transmission to the Sponsor.

By signing this protocol, the investigator agrees to treat all participant data used and disclosed in connection with this study in accordance with all applicable privacy laws, rules, and regulations.

10.1.3.3 Confidentiality of IRB/IEC Information

The Sponsor is required to record the name and address of each IRB/IEC that reviews and approves this study. The Sponsor is also required to document that each IRB/IEC meets regulatory and ICH GCP requirements by requesting and maintaining records of the names

and qualifications of the IRB/IEC members and to make these records available for regulatory agency review upon request by those agencies.

10.1.4 Committees Structure

10.1.4.1 Executive Oversight Committee

The EOC is comprised of members of Sponsor Senior Management. The EOC will receive and decide on any recommendations made by the DMC regarding the study.

10.1.4.2 External Data Monitoring Committee

To supplement the routine study monitoring outlined in this protocol, an external DMC will monitor the interim data from this study. The voting members of the committee are external to the Sponsor. The members of the DMC must not be involved with the study in any other way (eg, they cannot be study investigators) and must have no competing interests that could affect their roles with respect to the study.

The DMC will make recommendations to the EOC regarding steps to ensure both participant safety and the continued ethical integrity of the study. Also, the DMC will review interim study results, consider the overall risk and benefit to study participants (Section 9.7) and recommend to the EOC whether the study should continue in accordance with the protocol.

Specific details regarding composition, responsibilities, and governance, including the roles and responsibilities of the various members and the Sponsor protocol team; meeting facilitation; the study governance structure; and requirements for and proper documentation of DMC reports, minutes, and recommendations will be described in the DMC charter that is reviewed and approved by all the DMC members.

10.1.4.3 Scientific Advisory Committee (SAC)

This study was developed in collaboration with a SAC. The SAC is comprised of both Sponsor and non-Sponsor scientific experts who provide scientific and strategic guidance on various aspects of the clinical trial and/or development, which may include to study design, interpretation of study results, and subsequent peer-reviewed scientific publications.

10.1.5 Publication Policy

The results of this study may be published or presented at scientific meetings. The Sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement.

If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.

Authorship will be determined by mutual agreement and in line with ICMJE authorship requirements.

10.1.6 Compliance with Study Registration and Results Posting Requirements

Under the terms of the FDAAA of 2007 and the EMA clinical trials Regulation 536/2014, the Sponsor of the study is solely responsible for determining whether the study and its results are subject to the requirements for submission to <http://www.clinicaltrials.gov>, www.clinicaltrialsregister.eu, <https://euclinicaltrials.eu>, or other local registries. MSD, as Sponsor of this study, will review this protocol and submit the information necessary to fulfill these requirements. MSD entries are not limited to FDAAA or the EMA clinical trials Regulation 536/2014 mandated trials. Information posted will allow participants to identify potentially appropriate studies for their disease conditions and pursue participation by calling a central contact number for further information on appropriate study locations and study-site contact information.

By signing this protocol, the investigator acknowledges that the statutory obligations under FDAAA, the EMA clinical trials Regulation 536/2014, or other locally mandated registries are that of the Sponsor and agrees not to submit any information about this study or its results to those registries.

10.1.7 Compliance with Law, Audit, and Debarment

By signing this protocol, the investigator agrees to conduct the study in an efficient and diligent manner and in conformance with this protocol; generally accepted standards of GCP (eg, ICH GCP: Consolidated Guideline and other generally accepted standards of GCP); and all applicable federal, state and local laws, rules and regulations relating to the conduct of the clinical study.

The Code of Conduct, a collection of goals and considerations that govern the ethical and scientific conduct of clinical investigations sponsored by MSD, is provided in this appendix under the Code of Conduct for Clinical Trials.

The investigator agrees not to seek reimbursement from participants, their insurance providers, or from government programs for procedures included as part of the study reimbursed to the investigator by the Sponsor.

The investigator will promptly inform the Sponsor of any regulatory authority inspection conducted for this study.

The investigator agrees to provide the Sponsor with relevant information from inspection observations/findings to allow the Sponsor to assist in responding to any citations resulting from regulatory authority inspection and will provide the Sponsor with a copy of the proposed response for consultation before submission to the regulatory authority.

Persons debarred from conducting or working on clinical studies by any court or regulatory authority will not be allowed to conduct or work on this Sponsor's studies. The investigator will immediately disclose in writing to the Sponsor if any person who is involved in

conducting the study is debarred or if any proceeding for debarment is pending or, to the best of the investigator's knowledge, threatened.

10.1.8 Data Quality Assurance

All participant data relating to the study will be recorded on printed or electronic CRF unless transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator or qualified designee is responsible for verifying that data entries are accurate and correct by physically or electronically signing the CRF.

Detailed information regarding Data Management procedures for this protocol will be provided separately.

The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF.

The investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents.

Study documentation will be promptly and fully disclosed to the Sponsor by the investigator upon request and also shall be made available at the study site upon request for inspection, copying, review, and audit at reasonable times by representatives of the Sponsor or any regulatory authorities. The investigator agrees to promptly take any reasonable steps that are requested by the Sponsor or any regulatory authorities as a result of an audit or inspection to cure deficiencies in the study documentation and worksheets/CRFs.

The Sponsor or designee is responsible for the data management of this study including quality checking of the data.

Study monitors will perform ongoing source data review and verification to confirm that data entered into the CRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.

Records and documents, including participants' documented informed consent, pertaining to the conduct of this study must be retained by the investigator for 15 years after study completion unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor.

10.1.9 Source Documents

Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected. The investigator/institution should maintain adequate and accurate source documents and study records that include all pertinent observations on each of the site's participants. Source documents and data should be attributable, legible,

contemporaneous, original, accurate, and complete. Changes to source data should be traceable, should not obscure the original entry, and should be explained if necessary (eg, via an audit trail). Source documents are filed at the investigator's site.

Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator/institution may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

10.1.10 Study and Site Closure

The Sponsor or its designee may stop the study or study-site participation in the study for medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, regulations, and GCP.

In the event the Sponsor prematurely terminates a particular study site, the Sponsor or designee will promptly notify that study site's IRB/IEC as specified by applicable regulatory requirement(s).

10.2 Appendix 2: Clinical Laboratory Tests

- The tests detailed in Table 7 will be performed by the local laboratory.
- Protocol-specific requirements for inclusion or exclusion of participants are detailed in Section 5 of the protocol.
- Additional tests may be performed at any time during the study as determined necessary by the investigator or required by local regulations.

Table 7 Protocol-required Safety Laboratory Assessments

Laboratory Assessments	Parameters
Pregnancy Testing	<ul style="list-style-type: none"> • Highly sensitive serum or urine hCG pregnancy test (as needed for POCBP)
hCG=human chorionic gonadotropin; POCBP=participants of childbearing potential.	

The investigator (or medically qualified designee) must document their review of each laboratory safety report.

Table 8 Blood Volumes for Participants Included in the Base Study

	Visit 1	Visit 3	Total
Parameter	Approximate Blood Volume		
Immunogenicity assessment	30 mL	30 mL	60 mL
DNA for Future Biomedical Research ^a	8.5 mL	N/A	8.5 mL
Expected total	38.5 mL	30 mL	68.5 mL
DNA=deoxyribonucleic acid; N/A=not applicable.			
^a Samples for future biomedical research will only be obtained from participants who provide separate consent for collection of this optional sample.			

Table 9 Blood Volumes for Participants Included in the Immunogenicity Follow-up Substudy (Includes Blood Volumes Required for the Base Study)

	Visit 1	Visit 3	Visit 5	Visit 6	Visit 7	Visit 8	Total
Parameter	Approximate Blood Volume						
Immunogenicity assessment	30 mL	30 mL	30 mL	30 mL	30 mL	30 mL	180 mL
DNA for Future Biomedical Research ^a	8.5 mL	N/A	N/A	N/A	N/A	N/A	8.5 mL
Expected total	38.5 mL	30 mL	30 mL	30 mL	30 mL	30 mL	188.5 mL
DNA=deoxyribonucleic acid; N/A=not applicable.							
^a Samples for future biomedical research will only be obtained from participants who provide separate consent for collection of this optional sample.							

Table 10 Blood Volumes for Participants Included in the PBMC Substudy
 (Includes Blood Volumes Required for the Base Study)

	Visit 1	Visit 3	Visit 4	Visit 5	Visit 6	Total
Parameter	Approximate Blood Volume					
Immunogenicity assessment	30 mL	30 mL	30 mL	30 mL	30 mL	150 mL
PBMC evaluation	50 mL	50 mL	50 mL	50 mL	50 mL	250 mL
DNA for Future Biomedical Research ^a	8.5 mL	N/A	N/A	N/A	N/A	8.5 mL
Expected total	88.5 mL	80 mL	80 mL	80 mL	80 mL	408.5 mL
DNA=deoxyribonucleic acid; N/A=not applicable; PBMC=peripheral blood mononuclear cell.						
^a Samples for future biomedical research will only be obtained from participants who provide separate consent for collection of this optional sample.						

Table 11 Blood Volumes for Participants Included in the Immunogenicity Follow-up Substudy and PBMC Substudy (Includes Blood Volumes Required for the Base Study)

	Visit 1	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Total
Parameter	Approximate Blood Volume							
Immunogenicity assessment	30 mL	30 mL	30 mL	30 mL	30 mL	30 mL	30 mL	210 mL
PBMC evaluation	50 mL	50 mL	50 mL	50 mL	50 mL	N/A	N/A	250 mL
DNA for Future Biomedical Research ^a	8.5 mL	N/A	N/A	N/A	N/A	N/A	N/A	8.5 mL
Expected total	88.5 mL	80 mL	80 mL	80 mL	80 mL	30 mL	30 mL	468.5 mL
DNA=deoxyribonucleic acid; N/A=not applicable; PBMC=peripheral blood mononuclear cell.								
^a Samples for future biomedical research will only be obtained from participants who provide separate consent for collection of this optional sample.								

10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting

10.3.1 Definitions of Medication Error, Misuse, and Abuse

Medication error

This is an unintended failure in the drug treatment process that leads to or has the potential to lead to harm to the patient.

Misuse

This refers to situations where the medicinal product is intentionally and inappropriately used not in accordance with the terms of the product information.

Abuse

This corresponds to the persistent or sporadic intentional, excessive use of a medicinal product for a perceived psychological or physiological reward or desired nontherapeutic effect.

10.3.2 Definition of AE

AE definition

- An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
- Note: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
- Note: For purposes of AE definition, study intervention includes any pharmaceutical product, biological product, vaccine, diagnostic agent, medical device, combination product, or protocol-specified procedure whether investigational or marketed (including placebo, active comparator product, or run-in intervention), manufactured by, licensed by, provided by, or distributed by the Sponsor for human use in this study.

Events meeting the AE definition

- Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator.
- Exacerbation of a chronic or intermittent preexisting condition including either an increase in frequency and/or intensity of the condition.
- New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study.

- Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
- Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication.
- For all reports of overdose (whether accidental or intentional) with an associated AE, the AE term should reflect the clinical symptoms or abnormal test result. An overdose without any associated clinical symptoms or abnormal laboratory results is reported using the terminology “accidental or intentional overdose without adverse effect.”
- Any new cancer or progression of existing cancer.

Events NOT meeting the AE definition

- Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the procedure is the AE.
- Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital).
- Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present or detected at the start of the study that do not worsen.
- Surgical procedure(s) planned prior to informed consent to treat a preexisting condition that has not worsened.
- Refer to Section 8.4.6 for protocol-specific exceptions.

Definition of Unsolicited and Solicited AE

- An unsolicited AE is an AE that was not solicited using a VRC and that is communicated by a participant/participant’s legally authorized representative who has signed the informed consent. Unsolicited AEs include serious and nonserious AEs.
- Solicited AEs are predefined local (at the injection/administration site) and systemic events for which the participant/participant’s legally authorized representative is specifically questioned, and which are noted by the participant/participant’s legally authorized representative in their VRC.

10.3.3 Definition of SAE

If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met.

An SAE is defined as any untoward medical occurrence that, at any dose:

- a. Results in death
- b. Is life-threatening
 - The term “life-threatening” in the definition of “serious” refers to an event in which the participant was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.

- c. Requires inpatient hospitalization or prolongation of existing hospitalization
 - Hospitalization is defined as an inpatient admission, regardless of length of stay, even if the hospitalization is a precautionary measure for continued observation. (Note: Hospitalization for an elective procedure to treat a preexisting condition that has not worsened is not an SAE.) A preexisting condition is a clinical condition that is diagnosed prior to the use of an MSD product and is documented in the participant's medical history.
- d. Results in persistent or significant disability/incapacity
 - The term disability means a substantial disruption of a person's ability to conduct normal life functions.
 - This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) that may interfere with or prevent everyday life functions but do not constitute a substantial disruption.
- e. Is a congenital anomaly/birth defect
 - In offspring of participant taking the product regardless of time to diagnosis.
- f. Other important medical events
 - Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent 1 of the other outcomes listed in the above definition. These events should usually be considered serious.
 - Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

10.3.4 Additional Events Reported

Additional events that require reporting

In addition to the above criteria, AEs meeting either of the below criteria, although not serious per ICH definition, are reportable to the Sponsor.

- Is a cancer.
- Is associated with an overdose.

10.3.5 Recording AE and SAE

AE and SAE recording

- When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (eg, hospital progress notes, laboratory, and diagnostics reports) related to the event.
- The investigator will record all relevant AE/SAE information on the AE CRFs/worksheets at each examination.
- It is not acceptable for the investigator to send photocopies of the participant's medical records to the Sponsor in lieu of completion of the AE CRF page.
- There may be instances when copies of medical records for certain cases are requested by the Sponsor. In this case, all participant identifiers, with the exception of the participant number, will be blinded on the copies of the medical records before submission to the Sponsor.
- The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.

Assessment of intensity

- An event is defined as "serious" when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, not when it is rated as severe.
- The investigator will assess the overall intensity of each AE and SAE (and other reportable event) reported during the study. An overall intensity grade will be assigned to injection-site AEs, specific systemic AEs, other systemic AEs, and vital sign (temperature) AEs as shown in the following tables. The overall intensity grading scales used in this study are adapted from the "FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007" [Food and Drug Administration 2007].

Injection-site AE Overall Intensity Grading Scale

Injection-Site Reaction to Study Vaccine/Placebo	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially Life-threatening (Grade 4)
Injection-site AEs occurring Days 1 through 5 following receipt of study vaccine/placebo				
Pain/Tenderness	Does not interfere with activity	Repeated use of nonnarcotic pain reliever >24 hours or interferes with activity	Any use of narcotic pain reliever or prevents daily activity	ED visit or hospitalization
Erythema/Redness	Size measured as ≤5 cm	Size measured as 5.1 to 10 cm	Size measured as >10 cm	Necrosis or exfoliative dermatitis or results in ED visit or hospitalization
Swelling	Size measured as ≤5 cm	Size measured as 5.1 to 10 cm	Size measured as >10 cm	Necrosis or ED visit or hospitalization
Other	Does not interfere with activity	Repeated use of nonnarcotic pain reliever >24 hours or interferes with activity	Any use of narcotic pain reliever or prevents daily activity	ED visit or hospitalization
Any injection-site reaction that begins ≥6 days after receipt of study vaccine/placebo				
Pain/Tenderness Erythema/Redness Swelling Other	Does not interfere with activity	Repeated use of nonnarcotic pain reliever >24 hours or interferes with activity	Any use of narcotic pain reliever or prevents daily activity	ED visit or hospitalization
AE=adverse event; ED=emergency department. The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food and Drug Administration 2007].				

Specific Systemic AE Overall Intensity Grading Scale

Systemic (General)	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially Life-threatening (Grade 4)
Headache	No interference with activity	Repeated use of nonnarcotic pain reliever >24 hours or some interference with activity	Significant; any use of narcotic pain reliever or prevents daily activity	ED visit or hospitalization
Fatigue	No interference with activity	Some interference with activity	Significant; prevents daily activity	ED visit or hospitalization
Myalgia	No interference with activity	Some interference with activity	Significant; prevents daily activity	ED visit or hospitalization

ED=emergency department.

The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food and Drug Administration 2007].

Other Systemic AE Overall Intensity Grading Scale

Systemic Illness ^a	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially Life-threatening (Grade 4) ^b
Illness or clinical AE (as defined according to applicable regulations)	No interference with activity	Some interference with activity not requiring medical intervention	Prevents daily activity and required medical intervention	ED visit or hospitalization

AE=adverse event; ED=emergency department; eVRC=electronic Vaccine Report Card; SAE=serious adverse event
 The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food and Drug Administration 2007].

^a Based on information provided by the participant on the eVRC and verbally during the eVRC review during the primary safety follow-up period. For SAEs reported beyond the primary safety follow-up period, grading will be based upon the initial report and/or follow-up of the event.

^b AEs resulting in death will be assessed as Grade 4.

Vital Sign (Temperature) Overall Intensity Grading Scale

Vital Signs ^a	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially Life-threatening (Grade 4)
Fever (°C) ^b	38.0 to 38.4	38.5 to 38.9	39.0 to 40.0	>40.0
(°F) ^b	100.4 to 101.1	101.2 to 102.0	102.1 to 104.0	>104.0

The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food and Drug Administration 2007].

^a Participant should be at rest for all vital sign requirements.

^b Oral temperature; no recent hot or cold beverages or smoking.

Assessment of causality

- Did the study intervention cause the AE?
- The determination of the likelihood that the study intervention caused the AE will be provided by an investigator who is a qualified physician. The investigator's signed/dated initials on the source document or worksheet that supports the causality noted on the AE form, ensures that a medically qualified assessment of causality was done. This initialed document must be retained for the required regulatory time frame. The criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test product and the AE based on the available information.
- **The following components are to be used to assess the relationship between the study intervention and the AE; the greater the correlation with the components and their respective elements (in number and/or intensity), the more likely the study intervention caused the AE:**
 - **Exposure:** Is there evidence that the participant was actually exposed to the study intervention such as: reliable history, acceptable compliance assessment (diary, etc.), seroconversion or identification of vaccine virus in bodily specimen?
 - **Time Course:** Did the AE follow in a reasonable temporal sequence from administration of the study intervention? Is the time of onset of the AE compatible with a vaccine-induced effect?
 - **Likely Cause:** Is the AE not reasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host or environmental factors?
 - **Rechallenge:** Was the participant reexposed to the study intervention in the study?
 - If yes, did the AE recur or worsen?
 - If yes, this is a positive rechallenge.
 - If no, this is a negative rechallenge.(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability; (2) the study is a single-dose vaccine study; or (3) study intervention(s) is/are used only 1 time.)

NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND MAY HAVE BEEN CAUSED BY THE STUDY INTERVENTION, OR IF REEXPOSURE TO THE STUDY INTERVENTION POSES ADDITIONAL POTENTIAL SIGNIFICANT RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE SPONSOR CLINICAL DIRECTOR, AND IF REQUIRED, THE IRB/IEC.

- **Consistency with study intervention profile:** Is the clinical/pathological presentation of the AE consistent with previous knowledge regarding the study intervention or drug class pharmacology or toxicology?
- The assessment of relationship will be reported on the CRFs/worksheets by an investigator who is a qualified physician according to their best clinical judgment, including consideration of the above elements.

- Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a study intervention relationship).
 - Yes, there is a reasonable possibility of study intervention relationship:
 - There is evidence of exposure to the study intervention. The temporal sequence of the AE onset relative to the administration of the study intervention is reasonable. The AE is more likely explained by the study intervention than by another cause.
 - No, there is not a reasonable possibility of study intervention relationship:
 - Participant did not receive the study intervention OR temporal sequence of the AE onset relative to administration of the study intervention is not reasonable OR the AE is more likely explained by another cause than the study intervention. (Also entered for a participant with overdose without an associated AE.)
- The investigator must review and provide an assessment of causality for each AE/SAE and document this in the medical notes.
- There may be situations in which an SAE has occurred and the investigator has minimal information to include in the initial report to the Sponsor. However, it is very important that the investigator always make an assessment of causality for every event before the initial transmission of the SAE data to the Sponsor.
- The investigator may change their opinion of causality in light of follow-up information and send an SAE follow-up report with the updated causality assessment.
- The causality assessment is 1 of the criteria used when determining regulatory reporting requirements.

Follow-up of AE and SAE

- The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by Sponsor to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals.
- New or updated information will be recorded in the CRF.
- The investigator will submit any updated SAE data to the Sponsor within 24 hours of receipt of the information.

10.3.6 Reporting of AEs, SAEs, and Other Reportable Safety Events to the Sponsor

AE, SAE, and other reportable safety event reporting to Sponsor via electronic data collection tool

- The primary mechanism for reporting to the Sponsor will be the EDC tool.
 - Electronic reporting procedures can be found in the EDC data entry guidelines (or equivalent).
 - If the electronic system is unavailable for more than 24 hours, then the site will use the paper AE Reporting form.
 - Reference Section 8.4.1 for reporting time requirements.

- The site will enter the SAE data into the electronic system as soon as it becomes available.
- After the study is completed at a given site, the EDC tool will be taken off-line to prevent the entry of new data or changes to existing data.
- If a site receives a report of a new SAE from a study participant or receives updated data on a previously reported SAE after the EDC tool has been taken off-line, then the site can report this information on a paper SAE form or by telephone (see next section).
- Contacts for SAE reporting can be found in the Investigator Study File Binder (or equivalent).

SAE reporting to the Sponsor via paper CRF

- If the EDC tool is not operational, facsimile transmission or secure email of the SAE paper CRF is the preferred method to transmit this information to the Sponsor.
- In rare circumstances and in the absence of facsimile equipment, notification by telephone is acceptable with a copy of the SAE data collection tool sent by overnight mail or courier service.
- Initial notification via telephone does not replace the need for the investigator to complete and sign the SAE CRF pages within the designated reporting time frames.
- Contacts and instructions for SAE reporting and paper reporting procedures can be found in the Investigator Study File Binder (or equivalent).

10.4 Appendix 4: Medical Device and Drug–Device Combination Products: Product Quality Complaints/Malfunctions: Definitions, Recording, and Follow-up

The recording and follow-up procedures described in this protocol apply to all medical devices as described below. For purposes of this section, medical devices in scope for device information collection include devices intended to be used by a study participant according to the study protocol that are manufactured by the Sponsor or for the Sponsor by a third party, licensed by the Sponsor for human use and/or drug–device combination products as listed in Section 6.1.1. Product Quality Complaints/Malfunctions must be reported to the Sponsor.

10.4.1 Definitions

Combination Product – A product comprised of 2 or more regulated components (ie, a drug and a device; a biologic and device; a biologic and a drug; or a drug, a device, and a biologic). Combination products can be single entity, copackaged, or colabeled.

Complaint – Any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device after it is released for distribution. This would include PQC, AE, and customer feedback.

A complaint does not necessarily need to involve a user or any other person.

Constituent Part – A drug, device, or biological product that is part of a combination product.

Customer Feedback – A report that does not allege a PQC or defect and has no relevant safety information/untoward event associated with it (eg, goodwill or courtesy replacement, consumer preference or suggestion, remark that may suggest an improvement in the functionality or quality of a medical device, or device like features of a drug delivery system).

Malfunction – The failure of a device to meet its performance specifications or otherwise perform as intended.

Medical Device – Any instrument, apparatus, appliance, material, or other article, whether used alone or in combination, including the software necessary for its proper application intended by the MANUFACTURER to be used for human beings for the purpose of:

- diagnosis, prevention, monitoring, treatment, or alleviation of disease,
- diagnosis, monitoring, treatment, alleviation of, or compensation for an injury or handicap,
- investigation, replacement, or modification of the anatomy or of a physiological process,
- control of conception,

and which does not achieve its principal intended action in or on the human body by pharmacological, immunological, or metabolic means, but which may be assisted in its function by such means.

PQC – Any communication that describes a potential defect related to the identity, strength, quality, purity, or performance of a product identified by external customers. This includes potential device or device component malfunctions. Note: A report of Lack or Limited Efficacy is considered an AE rather than a PQC.

Serious Injury – An injury or illness that:

1. Is life-threatening,
2. Results in permanent impairment of a body function or permanent damage to a body structure, or
3. Necessitates medical or surgical intervention to preclude permanent impairment of a body function or permanent damage to a body structure.

Permanent means irreversible impairment or damage to a body structure or function, excluding trivial impairment or damage.

10.4.2 Recording, Assessing Causality, and Follow-up of PQCs/Malfunctions

Recording

When a complaint including PQC/malfunction occurs it is the responsibility of the investigator to review all documentation (eg, hospital progress notes, laboratory reports, and diagnostic reports) related to the event.

Events occurring during the study will be recorded in the participant’s medical records, in accordance with the investigator’s normal clinical practice, and on the appropriate CRF (paper or electronic) as per instructions provided in the data entry guidelines. Medical device/device constituent part of drug-device combination product information will be collected and reported to the Sponsor in the same time frame as SAEs as per Section 8.4.1 via CRF (paper or electronic). PQCs/malfunctions must be reported to the Sponsor.

Assessing Causality

A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship.

The investigator will use clinical judgment to determine the relationship.

Alternative causes such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study intervention administration should be considered and investigated.

Follow-up

The investigator will perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by the Sponsor to elucidate the nature and/or causality of the event as complete as possible.

10.5 Appendix 5: Contraceptive Guidance

10.5.1 Definitions

Participants of Childbearing Potential (POCBP)

A participant assigned female sex at birth is considered fertile following menarche and capable of becoming pregnant until becoming postmenopausal unless permanently sterile (see below):

If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of study intervention, additional evaluation should be considered.

Participants assigned female sex at birth who are in the following categories are not capable of becoming pregnant and, therefore, not considered POCPB:

- Premenarchal
- Premenopausal with 1 of the following:
 - Documented hysterectomy
 - Documented bilateral salpingectomy
 - Documented bilateral oophorectomy

For individuals with permanent infertility due to an alternate medical cause other than the above (eg, Müllerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.

Note: Documentation can come from the site personnel's review of the participant's medical records, medical examination, or medical history interview.

- Postmenopausal
 - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
 - A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in participants assigned female sex at birth who are not using hormonal contraception or HRT. However, in the absence of 12 months of amenorrhea, confirmation with 2 FSH measurements in the postmenopausal range is required.
 - Participants assigned female sex at birth who are on HRT and whose menopausal status is in doubt will be required to use one of the nonhormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.

10.5.2 Contraceptive Requirements

<p>Contraceptives allowed during the study include:</p>
<p>Highly Effective Contraceptive Methods That Have Low User Dependency^a <i>Failure rate of <1% per year when used consistently and correctly.</i></p>
<ul style="list-style-type: none"> • Progestogen- only contraceptive implant^b • IUS^c • Non-hormonal IUD • Bilateral tubal occlusion
<ul style="list-style-type: none"> • Azoospermic partner (vasectomized or secondary to medical cause, confirmed by medical history) All sexual partner(s) of the POCBP must be azoospermic. The participant must provide verbal confirmation of partner azoospermia during Medical History. If not, an additional highly effective method of contraception should be used. A spermatogenesis cycle is approximately 90 days.
<p>Highly Effective Contraceptive Methods That Are User Dependent^a <i>Failure rate of <1% per year when used consistently and correctly.</i></p>
<ul style="list-style-type: none"> • Combined (estrogen- and progestogen- containing) hormonal contraception^c <ul style="list-style-type: none"> - Oral - Intravaginal - Transdermal - Injectable
<ul style="list-style-type: none"> • Progestogen-only hormonal contraception^c <ul style="list-style-type: none"> - Oral - Injectable
<p>Sexual Abstinence</p> <ul style="list-style-type: none"> • All sexual partner(s) of the POCBP must be azoospermic. The participant must provide verbal confirmation of partner azoospermia during Medical History. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
<p>Methods That Are Not Considered Highly Effective <i>Failure rate of >1% per year when used consistently and correctly.</i></p>
<ul style="list-style-type: none"> • Progesterone-only hormonal contraception where inhibition of ovulation is not the primary mode of action • Penile/external or vaginal/internal^d condom with or without spermicide • Cervical cap, diaphragm, or sponge with spermicide • A combination of penile/external condom with either cervical cap, diaphragm, or sponge with spermicide (double barrier methods).
<p>^a Typical use failure rates are higher than perfect-use failure rates (ie, when used consistently and correctly).</p> <p>^b If locally required, in accordance with CTFG guidelines, acceptable hormonal contraceptives are limited to those which inhibit ovulation.</p> <p>^c IUS is a progestin releasing IUD.</p> <p>^d Vaginal/internal condom used for contraceptive purposes.</p> <p>Note: The following are not acceptable methods of contraception:</p> <ul style="list-style-type: none"> - Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and LAM. - Penile/external and vaginal/internal condom should not be used together (due to risk of failure with friction).

10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical Research

1. Definitions

- a. Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.¹
- b. Pharmacogenomics: The investigation of variations of DNA and RNA characteristics as related to drug/vaccine response.²
- c. Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of variations in DNA sequence on drug/vaccine response.²
- d. DNA: Deoxyribonucleic acid.
- e. RNA: Ribonucleic acid.

2. Scope of Future Biomedical Research^{3, 4}

The specimens consented and/or collected in this study as outlined in Section 8.9 will be used in various experiments to understand:

- The biology of how drugs/vaccines work
- Biomarkers responsible for how a drug/vaccine enters and is removed by the body
- Other pathways with which drugs/vaccines may interact
- The biology of disease

The specimen(s) may be used for future assay development and/or drug/vaccine development.

It is now well recognized that information obtained from studying and testing clinical specimens offers unique opportunities to enhance our understanding of how individuals respond to drugs/vaccines, enhance our understanding of human disease, and ultimately improve public health through development of novel treatments targeted to populations with the greatest need. All specimens will be used by the Sponsor or those working for or with the Sponsor.

3. Summary of Procedures for Future Biomedical Research^{3, 4}

- a. Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in future biomedical research.

b. Informed Consent

Informed consent for specimens (ie, DNA, RNA, protein, etc) will be obtained during screening for protocol enrollment from all participants or legal guardians, at a study visit by the investigator or his or her designate. Informed consent for future biomedical research should be presented to the participants on the visit designated in the SoA. If delayed, present consent at next possible Participant Visit. Consent forms signed by the participant will be kept at the clinical study site under secure storage for regulatory reasons.

A template of each study site's approved informed consent will be stored in the Sponsor's clinical document repository.

c. eCRF Documentation for Future Biomedical Research Specimens

Documentation of participant consent for future biomedical research will be captured in the eCRFs. Any specimens for which such an informed consent cannot be verified will be destroyed.

d. Future Biomedical Research Specimen(s)

Collection of specimens for future biomedical research will be performed as outlined in the SoA. In general, if additional blood specimens are being collected for future biomedical research, these will usually be obtained at a time when the participant is having blood drawn for other study purposes.

4. Confidential Participant Information for Future Biomedical Research^{3, 4}

In order to optimize the research that can be conducted with future biomedical research specimens, it is critical to link participants' clinical information with future test results. In fact, little or no research can be conducted without connecting the clinical study data to the specimen. The clinical data allow specific analyses to be conducted. Knowing participant characteristics like sex, age, medical history, and intervention outcomes is critical to understanding clinical context of analytical results.

To maintain privacy of information collected from specimens obtained for future biomedical research, the Sponsor has developed secure policies and procedures. All specimens will be single coded per ICH E15 guidelines as described below.

At the clinical study site, unique codes will be placed on the future biomedical research specimens. This code is a random number that does not contain any personally identifying information embedded within it. The link (or key) between participant identifiers and this unique code will be held at the study site. No personal identifiers will appear on the specimen tube.

5. Biorepository Specimen Usage^{3, 4}

Specimens obtained for the Sponsor will be used for analyses using good scientific practices. Analyses using the future biomedical research specimens may be performed by the Sponsor, or an additional third party (eg, a university investigator) designated by the Sponsor. The investigator conducting the analysis will follow the Sponsor's privacy and confidentiality requirements. Any contracted third-party analyses will conform to the

specific scope of analysis outlined in future biomedical research protocol and consent. Future biomedical research specimens remaining with the third party after specific analysis is performed will be reported to the Sponsor.

6. Withdrawal From Future Biomedical Research^{3, 4}

Participants may withdraw their consent for FBR and ask that their biospecimens not be used for FBR. Participants may withdraw consent at any time by contacting the study investigator. If medical records for the study are still available, the investigator will contact the Sponsor using the designated mailbox (clinical.specimen.management@MSD.com). Subsequently, the participant's specimens will be flagged in the biorepository and restricted to study use only. If specimens were collected from study participants specifically for FBR, these specimens will be removed from the biorepository and destroyed. Documentation will be sent to the investigator confirming withdrawal and/or destruction, if applicable. It is the responsibility of the investigator to inform the participant of completion of the withdrawal and/or destruction, if applicable. Any analyses in progress at the time of request for withdrawal/destruction or already performed before the request being received by the Sponsor will continue to be used as part of the overall research study data and results. No new analyses would be generated after the request is received.

If the medical records for the study are no longer available (eg, if the investigator is no longer required by regulatory authorities to retain the study records) or the specimens have been completely anonymized, there will no longer be a link between the participant's personal information and their specimens. In this situation, the request for withdrawal of consent and/or destruction cannot be processed.

7. Retention of Specimens^{3, 4}

Future biomedical research specimens will be stored in the biorepository for potential analysis for up to 20 years from the end of the study. Specimens may be stored for longer if a regulatory or governmental authority has active questions that are being answered. In this special circumstance, specimens will be stored until these questions have been adequately addressed.

Specimens from the study site will be shipped to a central laboratory and then shipped to the Sponsor-designated biorepository. If a central laboratory is not used in a particular study, the study site will ship directly to the Sponsor-designated biorepository. The specimens will be stored under strict supervision in a limited access facility, which operates to assure the integrity of the specimens. Specimens will be destroyed according to Sponsor policies and procedures and this destruction will be documented in the biorepository database.

8. Data Security^{3,4}

Databases containing specimen information and test results are accessible only to the authorized Sponsor representatives and the designated study administrator research personnel and/or collaborators. Database user authentication is highly secure, and is accomplished using network security policies and practices based on international standards to protect against unauthorized access.

9. Reporting of Future Biomedical Research Data to Participants^{3,4}

No information obtained from exploratory laboratory studies will be reported to the participant, family, or physicians. Principle reasons not to inform or return results to the participant include lack of relevance to participant health, limitations of predictive capability, and concerns regarding misinterpretation.

If important research findings are discovered, the Sponsor may publish results, present results in national meetings, and make results accessible on a public website in order to rapidly report this information to doctors and participants. Participants will not be identified by name in any published reports about this study or in any other scientific publication or presentation.

10. Future Biomedical Research Study Population^{3,4}

Every effort will be made to recruit all participants diagnosed and treated on Sponsor clinical studies for future biomedical research.

11. Risks Versus Benefits of Future Biomedical Research^{3,4}

For future biomedical research, risks to the participant have been minimized and are described in the future biomedical research informed consent.

The Sponsor has developed strict security, policies, and procedures to address participant data privacy concerns. Data privacy risks are largely limited to rare situations involving possible breach of confidentiality. In this highly unlikely situation, there is risk that the information, like all medical information, may be misused.

12. Questions

Any questions related to the future biomedical research should be emailed directly to clinical.specimen.management@MSD.com.

13. References

1. National Cancer Institute [Internet]: Available from <https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45618>
2. International Council on Harmonisation [Internet]: E15: Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories. Available from <http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/definitions-for-genomic-biomarkers-pharmacogenomics-pharmacogenetics-genomic-data-and-sample-cod.html>

3. Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs and Investigational Site Staff. Available at <http://i-pwg.org/>
4. Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at <http://i-pwg.org/>

10.7 Appendix 7: Country-specific Requirements

10.7.1 Country-specific Requirements for South Korea

Section 5.2 Exclusion Criterion

13. Is currently participating in or has participated in an interventional clinical study with an investigational compound or device within 6 months of participating in this clinical study.

10.8 Appendix 8: Abbreviations

Abbreviation	Expanded Term
ABCs	Active Bacterial Core Surveillance
ACIP	Advisory Committee on Immunization Practices
AE	adverse event
APaT	All-Participants-as-Treated
CDC	Centers for Disease Control and Prevention
CFR	Code of Federal Regulations
CI	confidence interval
cLDA	constrained Longitudinal Data Analysis
CONSORT	Consolidated Standards of Reporting Trials
CRF	case report form
CSR	clinical study report
CTFG	Clinical Trial Facilitation Group
deOAc	de-O-acetylated
DMC	Data Monitoring Committee
DNA	deoxyribonucleic acid
ECG	electrocardiogram
ECI	event of clinical interest
ECL	electrochemiluminescence
eCRF	electronic Case Report Form
EDC	electronic data collection
ELISPOT	enzyme-linked immunosorbent spot
EMA	European Medicines Agency
EOC	Executive Oversight Committee
EU	European Union
eVRC	Electronic Vaccination Report Card
FAS	Full Analysis Set
FBR	Future Biomedical Research
FDA	Food and Drug Administration
FDAAA	Food and Drug Administration Amendments Act
FSH	follicle-stimulating hormone
GCP	Good Clinical Practice
GMC	geometric mean concentration
GMFR	geometric mean fold rise
GMT	geometric mean titer
hCG	human chorionic gonadotropin
HIV	human immunodeficiency virus
HRT	hormone-replacement therapy
IA(s)	interim analysis(es)
IB	Investigator's Brochure
ICF	Informed Consent Form
ICH	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

Abbreviation	Expanded Term
ICMJE	International Committee of Medical Journal Editors
IEC	Independent Ethics Committee
IgG	Immunoglobulin G
IM	intramuscular(ly)
IND	Investigational New Drug
IPD	invasive pneumococcal disease
IRB	Institutional Review Board
IRT	interactive response technology
IUD	intrauterine device
IUS	intrauterine hormone-releasing system
LDA	longitudinal data analysis
M&N	Miettinen and Nurminen
MOPA	Multiplexed Opsonophagocytic Assay
mRNA	messenger RNA
OPA	opsonophagocytic activity
PBMC	peripheral blood mononuclear cells
PCV	pneumococcal conjugate vaccine
PCV13	pneumococcal 13-valent conjugate vaccine (Prevnar 13™)
PCV15	pneumococcal 15-valent conjugate vaccine (VAXNEUVANCE™) (Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F)
PCV20	pneumococcal 20-valent conjugate vaccine (Prevnar 20™ / APEXXNAR™)
Pn ECL	pneumococcal electrochemiluminescence
PnPs	pneumococcal polysaccharide
POCBP	Participant/participants of childbearing potential
PP	per-protocol
PPSV23	pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX™23) (Serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F)
PQC	product quality compliant
REML	restricted maximum likelihood
RNA	ribonucleic acid
SAC	Scientific Advisory Committee
SAE	serious adverse event
SAP	Statistical Analysis Plan
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
SLAB	Supplemental laboratory test(s)
SoA	Schedule of Activities
sSAP	supplemental Statistical Analysis Plan
SUSAR	suspected unexpected serious adverse reaction
UK	United Kingdom
US	United States
VRC	Vaccination Report Card

11 REFERENCES

- [Anttila, M., et al 1999] Anttila M, Voutilainen M, Jääntti V, Eskola J, Käyhty H. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against *Streptococcus pneumoniae*. Clin Exp Immunol 1999;118(3):402-7. [03QY70]
- [Batah, J. 2018] Batah J, Varon E. Caisse Nationale de Retraite et de la Caisse de Prevoyance Sociale, Rapport d'activite 2018 (Epidemiologie 2017) [National Pension Fund and Social Security Fund, Activity Report 2018 (Epidemiology 2017)]. Creteil (France): Caisse Nationale de Retraite et de la Caisse de Prevoyance Sociale (CNRCPS), Centre National de Reference des Pneumocoques; 2018. 89 p. [06FYM4]
- [Bonnave, C., et al 2019] Bonnave C, Mertens D, Peetermans W, Cobbaert K, Ghesquiere B, Deschodt M, et al. Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe. Eur J Clin Microbiol Infect Dis. 2019;38:785-91. [05CZ9M]
- [Burton, Robert L. and Nahm, Moon H. 2006] Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006;13(9):1004-9. [03QT2R]
- [Centers for Disease Control and Prevention 2010] Centers for Disease Control and Prevention. Prevention of Pneumococcal Disease Among Infants and Children - Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine; Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59(RR-11):1-19. [03RSB6]

[Centers for Disease Control and Prevention 2015]	Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. 13th ed. Hamborsky J, Kroger A, Wolfe S, editors. Washington (DC): Department of Health and Human Services (HHS); c2015. Chapter 6, Vaccine administration; p. 79-106.	[0508PV]
[Clopper, C. J. and Pearson, E. S. 1934]	Clopper CJ and Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. <i>Biometrika</i> 1934;26(4):404-13.	[03Q0LW]
[CLOPPER, C. J. and PEARSON, E. S. 1934a]	Clopper CJ, Pearson ES. The use of confidence of fiducial limits illustrated in the case of the binomial. <i>Biometrika</i> 1934;26(4):404-13.	[03RRVC]
[Cripps, A. W., et al 2021]	Cripps AW, Folaranmi T, Johnson KD, Musey L, Niederman MS, Buchwald UK. Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. <i>Expert Rev Vaccines</i> . 2021;20(3):257-67.	[06D787]
[Curcio, D., et al 2015]	Curcio D, Cane A, Isturiz R. Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence. <i>Int J Infect Dis</i> . 2015;37:30-5.	[04VSHL]
[Demczuk, W. H. B., et al 2013]	Demczuk WHB, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, et al. Serotype distribution of invasive <i>Streptococcus pneumoniae</i> in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. <i>Can J Microbiol</i> 2013;59:778-88.	[03XKZ6]

[Demczuk, W. H. B., et al 2018]	Demczuk WHB, Martin I, Desai S, Griffith A, Caron-Poulin L, Lefebvre B, et al. Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010-2016. Vaccine. 2018;36:4701-7. Supplement material; 5 p.	[06FY94]
[Drijkoningen, J. J 2014]	Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014 May;20 Suppl 5:45-51.	[04NFHN]
[European Center for Disease Prevention and Control 2018a]	European Center for Disease Prevention and Control. Surveillance report: annual epidemiological report for 2016: invasive pneumococcal disease. Stockholm (Sweden): European Center for Disease Prevention and Control (ECDC) 2018 Aug. 12 p.	[052RH8]
[European Centre for Disease Prevention and Control 2020]	European Centre for Disease Prevention and Control. Invasive pneumococcal disease: annual epidemiological report for 2018. Stockholm (Sweden): European Centre for Disease Prevention and Control (ECDC); 2020 Sep. 11 p.	[07XGL2]
[European Centre for Disease Prevention and Control 2021b]	European Centre for Disease Prevention and Control [Internet]. Stockholm (Sweden): European Centre for Disease Prevention and Control (ECDC). Pneumococcal disease: recommended vaccinations; [cited 2021 Nov 25]; [about 5 screens]. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=25&SelectedCountryId ByDisease=-1 .	[07XGL0]

[European Centre for Disease Prevention and Control 2022]	Surveillance Atlas of Infectious Diseases [Internet]. Stockholm (Sweden): European Centre for Disease Prevention and Control (ECDC); c2022. ECDC surveillance atlas of infectious diseases - invasive pneumococcal disease confirmed cases, reported cases (2019); [cited 2022 Apr 15]. Available from: http://atlas.ecdc.europa.eu/public/index.aspx .	[080FJD]
[Farrington, C. P. 1990]	Farrington CP, Manning G. Test Statistics and Sample Size Formulae for Comparative Binomial Trials with Null Hypothesis of Non-Zero Risk Difference or Non-Unity Relative Risk. Stat Med Vol. 9,1447-1454 (1990)	[04FS6L]
[Food and Drug Administration 2007]	Food and Drug Administration. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Rockville, MD. Sep 2007.	[05B4S4]
[Golden, A. R., et al 2016]	Golden AR, Adam HJ, Zhanel GG. Invasive Streptococcus pneumoniae in Canada, 2011-2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. Vaccine. 2016 May 17;34(23):2527-30.	[04KWF0]
[Grabenstein, J. D. 2014]	Grabenstein JD, Musey LK. Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine. 2014;32:2399-405.	[053FFL]
[Hicks, L. A., et al 2007]	Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of Pneumococcal Disease Due to Non-Pneumococcal Conjugate Vaccine (PCV7) Serotypes in the United States during the Era of Widespread PCV7 Vaccination, 1998-2004. J Infect Dis 2007;196:1346-54.	[03QT0G]

[Independent Polling System Of Society 2017]	Independent Polling System Of Society. Adult pneumonia vaccination understanding in Europe: 65 years and over. Paris (France): Independent Polling System Of Society (Ipsos); 2017 Jul. 12 p.	[08306F]
[Janssens, J. P. 2004]	Janssens JP, Krause KH. Pneumonia in the very old. <i>Lancet Infect Dis.</i> 2004 Feb;4:112-24.	[04VTNJ]
[Jiang, Y., et al 2018]	Jiang Y, Yang X, Taniguchi K, Petigara T, Abe M. A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan. <i>J Med Econ.</i> 2018;21(7):687-97.	[082JJG]
[Kim, J. H., et al 2019]	Kim JH, Chun BC, Song JY, Kim HY, Bae IG, Kim DM, et al. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: a case-control study. <i>Vaccine.</i> 2019;37:2797-804.	[057TW6]
[Kobayashi, M., et al 2022]	Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. <i>MMWR Morb Mortal Wkly Rep.</i> 2022 Jan 28;71(4):109-17.	[07YPRJ]
[Lawrence, H., et al 2020]	Lawrence H, Pick H, Baskaran V, Daniel P, Rodrigo C, Ashton D, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. <i>PLoS Med.</i> 2020 Oct 23;17(10):e1003326.	[06D36L]

[Liang, K-Y and Zeger, S. L. 2000]	Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. <i>Sankhya: The Indian Journal of Statistics</i> 2000;62(Series B, Part 1):134-48.	[00V5V6]
[Manoff, S. B., et al 2010]	Manoff SB, Liss C, Caulfield MJ, Marchese RD, Silber J, Boslego J, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged \geq 65 years. <i>J Infect Dis</i> 2010;201(4):525-33.	[03RBYQ]
[Marcy, S. M., et al 2004]	Marcy SM, Kohl KS, Dagan R, Nalin D, Blum M, Connell Jones M, et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. <i>Vaccine</i> 2004;22:551-6.	[03PVW0]
[Matanock, A. 2018]	Matanock A. Estimating pneumococcal pneumonia burden among U.S. adults and progress on the research agenda for potential policy change. Slides presented at: Advisory Committee on Immunization Practices (ACIP) Meeting; 2018 Feb 21-22; Atlanta, GA.	[05B5W5]
[Miettinen, O. and Nurminen, M. 1985]	Miettinen O, Nurminen M. Comparative Analysis of Two Rates. <i>Stat Med</i> 1985;4:213-26.	[03QCDT]
[Miller, Elizabeth, et al 2011]	Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. <i>Lancet Infect Dis</i> 2011;11(10):760-8.	[03RKY7]

[Moore, M. R., et al 2015]	Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. <i>Lancet Infect Dis</i> . 2015 Feb 3. [Epub ahead of print].	[043MRP]
[Musher, D. M., et al 2010]	Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. <i>J Infect Dis</i> 2010;201(4):516-24.	[03RBW9]
[Nakano, S., et al 2016]	Nakano S, Fujisawa T, Ito Y, Chang B, Suga S, Noguchi T, et al. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive <i>Streptococcus pneumoniae</i> isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014. <i>Vaccine</i> . 2016;34:67-76.	[057R40]
[National Institute of Infectious Diseases 2018c]	National Institute of Infectious Diseases. [Current situation of invasive pneumococcal disease among children following the introduction of 13-valent pneumococcal conjugate vaccine]. <i>Infectious Agents Surveillance Report</i> . 2018 Jul;39(7):107-28. Japanese.	[06FHG4]
[Niederman, M. S., et al 2021]	Niederman MS, Folaranmi T, Buchwald UK, Musey L, Cripps AW, Johnson KD. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. <i>Expert Rev Vaccines</i> . 2021;20(3):243-55.	[06DC98]

[Papadatou, I., et al 2019]	Papadatou I, Tzovara I, Licciardi PV. The role of serotype-specific immunological memory in pneumococcal vaccination: current knowledge and future prospects. <i>Vaccines</i> . 2019 Jan 29;7:13.	[082M2X]
[Pilishvili, T. 2015]	Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. <i>Am J Prev Med</i> . 2015 Dec;49(6 suppl 4):S383-90.	[04WP9S]
[Pilishvili, Tamara, et al 2010]	Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. <i>J Infect Dis</i> 2010;201(1):32-41.	[03R5S4]
[Public Health Agency of Canada 2018b]	Public Health Agency of Canada. National laboratory surveillance of invasive streptococcal disease in Canada: annual summary 2018. Ottawa (ON): Public Health Agency of Canada (PHAC); 2018. 68 p.	[06FXRJ]
[Public Health England 2021]	Public Health England [Internet]. London (England): Public Health England (PHE). Pneumococcal disease infections caused by serotypes in Prevenar 13 and not in Prevenar 7; [updated 2021 Jan 28; cited 2021 Aug 21]; 6 p. Available from: https://www.gov.uk/government/publications/pneumococcal-disease-caused-by-strains-in-prevenar-13-and-not-in-prevenar-7-vaccine/pneumococcal-disease-infections-caused-by-serotypes-in-prevenar-13-and-not-in-prevenar-7 .	[06FYGJ]

[Public Health England 2021a]	Public Health England [Internet]. London (England): Public Health England (PHE). Pneumococcal disease infections caused by serotypes not in Prevenar 13 vaccine; [updated 2021 Jan 28; cited 2021 Aug 21]; 6 p. Available from: https://www.gov.uk/government/publications/pneumococcal-disease-caused-by-strains-not-covered-by-prevenar-13-vaccine/pneumococcal-disease-infections-caused-by-serotypes-not-in-prevenar-13-vaccine .	[06FYRM]
[Romero-Steiner, S., et al 1997]	Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997;4(4):415-22.	[03NWQ5]
[Simonsen, L., et al 2014]	Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014 May;2(5):387-94.	[04KVRV]
[Suzuki, M., et al 2017]	Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017 Mar;17:313-21.	[04YGY7]
[Thorrington, D., et al 2018]	Thorrington D, van Rossum L, Knol M, de Melker H, Rumke H, Hak E, et al. Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands. PLoS One. 2018 Feb 9;13(2):e0192640.	[082JJK]

[Tin Tin Htar, M., et al 2015]	Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis. 2015;15:419.	[05R8SZ]
[Troeger, C., et al 2018]	Troeger C, Blacker BF, Khalil IA, Rao PC, Cao S, Zimsen SRM, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018 Nov;18:1191-210.	[07XTBZ]
[U.S. Food and Drug Administration 2009]	U.S. Food and Drug Administration (CDER, CBER, CDRH). Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims [Internet]. Washington: U.S. Department of Health and Human Services; 2009. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf	[04MG9J]
[van der Linden, M., et al 2015]	van der Linden M, Falkenhorst G, Perniciaro S, Imohl M. Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS One. 2015 Jul 1;10(7):e0131494.	[04KVRy]
[van der Linden, M., et al 2019]	van der Linden M, Imohl M, Perniciaro S. Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PLoS One. 2019 Aug 1;14(8):e0220453. Erratum in: PLoS One. 2020 Jan 16;15(1):e0228126.	[06FY9H]
[van Hoek, A. J., et al 2012]	van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012 Jul;65(1):17-24.	[04NKDG]

[Waight, P. A., et al 2015]	Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. <i>Lancet Infect Dis.</i> 2015 May;15(5):535-43.	[04KTF2]
[Weycker, D., et al 2010]	Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. <i>Vaccine</i> 2010;28(31):4955-60.	[03RFMJ]
[World Health Organization 2020a]	SAGE Working Group. Pneumococcal vaccination of older adults, report of the sage working group on pneumococcal vaccines. Geneva (Switzerland): World Health Organization (WHO); 2020. 87 p.	[07ZG8H]
[Zhao, D., et al 2016]	Zhao D, Gai Tobe R, Cui M, He J, Wu B. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China. <i>Vaccine.</i> 2016;34:6158-65.	[082JJQ]